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"Everything should be made as simple as 
possible but not simpler" 
 
     Albert Einstein 
 
 
 
 
 
 Chapter 1: General introduction. 
 
 
 
Part I: Transcription. 
 
1.1.1 Introduction 
 
Regulation of gene expression is one of the major focal points 
in biochemistry today. Contributions from the fields of genetics, 
biochemistry and structural biology have created a w lth of data on 
the function of the network of multi-protein "molecular machines" that 
is involved in transcription. The emerging picture shows tight control 
on gene expression by balancing activation, repression and silencing. 
With the recent completion of the human genome sequencing project 
and the advent of high throughput methods such as genome wide 
screening using DNA microarrays, our insight is likely to increase 
even further. Yet it will take the combined effort of all these 
disciplines to truly gain understanding of the way genetic activity is 
controlled. 
 
1.1.2 Chromatin structure 
 
The entire human genome consists of over 3 billion base pairs 
(bp) [1]. In order to fit this much DNA into the nucleus, it needs to be 
tightly packaged. To achieve this, nuclear DNA is wrapped around 
protein complexes, which gives the DNA an appear ce like beads on 
a string. Each unit consists of about 200 bp of DNA, where 146 bp is 
wrapped around the protein complex called the histone octamer, while 
the remainder makes up the linker to the next nucleosome (Fig. 1). 
Each core complex contains two copies of the core histones (H2A, 
H2B, H3 and H4). A fifth histone (H1) is bound on the outside of the 
core. H1 can bind both DNA and core histones and is involved in 
forming an as yet uncharacterized higher order structure, providing 
further condensation the DNA. This structure is referred to as 
chromatin (reviewed in [2]). 
Chapter I - Introduction 
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Figure 1 
Beads-on-a-string structure of the core nucleosomes; the DNA is 
wrapped around the histone octamer, as shown in the cross-section 
through the core nucleosome complex crystal structure. 
 
 
Packaging of DNA into chromatin has a repressive effect on 
transcription by limiting the accessibility of the DNA for the 
transcription machinery. Since the naturally occurring form of nuclear 
DNA is chromatin bound, this repression and its alleviation have 
proven to be an important regulatory mechanism of transcription. 
Activation of transcription from a chromatin bound template requires 
a "loosening" of the nucleosome structure. This can be achieved by 
ATP-dependent chromatin remodeling complexes (discussed below) 
or by covalent modifications of the histone proteins. Specifically, the 
N-terminal tails of the core histones H3 and H4 can be acetylated by 
transcription activators containing histone acetyl transferase (HAT) 
activity. The targeted lysine residues are believed to be involved in 
DNA and inter-nucleosome contacts, promoting condensation of the 
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DNA in their unmodified form. Acetylation of these residues 
neutralizes their positive charge, which serves to decrease their 
interaction with the negatively charged DNA (reviewed in [3]). In 
addition, H1 is mono-ubiquitinated by TAFII250, which may target H1 
for ubiquitin-mediated degradation. A mutant TAFII250 lacking this 
activity was shown to repress transcription on two genes that require 
TAFII250 for activated transcription [4]. Thus one can speculate that 
removal of H1 from the chromatin complex might produce a similar 
effect as histone acetylation. 
The role of other modifications of histone proteins such as 
phosphorylation and methylation (reviewed in [5-7]) is less clear at 
present. In contrast to acetylation, methylation of histone tails (both on 
lysine and arginine residues) conserves the positive charge. Even 
though methylation would not have a similar effect as acetylation, it is 
definitely involed in the regulation of chromatin structure [8]. 
Furthermore, histone methylation can serve as a recognition marker 
for regulatory proteins. A recent example of this is the chromo-domain 
on the HP1 family of repressor proteins, which recognizes H3 
methylated on lysine 9 [9]. Finally, it has been shown that 
transcriptional co-activator CBP/p300 interacts with a histone 
methyltransferase in vivo, suggesting a link between acetylation and 
methylation and a role for histone methylation in transcription 
activation [10]. Phosphorylation of histones has long been coupled to 
condensation of the genome during mitosis [11]. This condensation 
would obviously lead to repression of transcription, however there are 
studies which link an increased acetylation of histone H3 after 
phosphorylation [12-14]. Thus histone phosphorylation may serve 
both to silence gene expression by genome condensation and to 
activate transcription by acting in concert with histone acetylation. 
Chromatin structure can also be rearranged without covalent 
modifications, but with the expense of ATP. For this purpose several 
families of ATP-dependent chromatin remodeling complexes exist in 
the cell, the most prominent of these being the SWI/SNF and the ISWI 
families (reviewed in [15-17]). These complexes are capable of 
rearranging higher order nucleosome structure, sliding of nucleosomes 
along template DNA and/or introducing negative superhelical tension 
on DNA. As in the case of covalent modifications of the histones, 
chromatin-remodeling complexes may both serve to activate and 
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repress transcription, depending on promoter context and the presence 
of transcription factors. Again, the accessibility of the DNA for the 
transcription machinery correlates to activation or repression. 
 
1.1.3 Basal transcription 
 
Transcription by RNA polymerase II (RNAPII) requires a 
minimal set of protein complexes known as the basal transcription 
factors, so termed for their requirement to reconstitute transcription 
activity on naked DNA templates in vitro. These factors cooperate to 
recruit RNAPII to a promoter and form the so-called preinitiation 
complex (PIC), which features the basal transcription factors and 
RNAPII bound to a partially unwound promoter region. In this PIC, 
the DNA may be wrapped around a complex consisting of RNAPII 
and the basal factors [18], reviewed in [19,20]. Key player in promoter 
recognition is the TATA binding protein (TBP). TBP recognizes and 
binds to a promoter specific sequence element, the TATA-box, which 
is present in the majority of RNAPII transcribed genes. In vivo, TBP is 
associated with a number of proteins of varying sizes, forming the 
basal transcription factor TFIID. These TATA associated factors 
(TAFIIs) may be present in different compositions in TFIID (reviewed 
in [21,22]). On promoters that do not contain a consensus TATA box, 
TAFIIs can interact with promoter elements to correctly position 
TFIID. These elements are the so-called initiator sequence (Inr), 
which overlaps the transcription start site, and the downstream 
promoter element (DPE), located around 30 bp downstream of the 
transcription start site [23-25]. In addition to DNA recognition, some 
TAFIIs were found to harbor enzymatic activities such as hi tone 
acetyl transferase (HAT), ATPase [26], kinase activity and, recently, 
ubiquitin conjugation activity [4]. TAFIIs are involved in mediating 
contacts between promoter specific transcription activators or 
cofactors and the basal transcription machinery. 
Once bound to a promoter, TFIID is stabilized by TFIIA, 
which contacts TBP, TAFII40 in TFIID and the DNA [27]. TFIIA is 
not considered a basal factor, as it is dispensable for the reconstitution 
of transcription in vitro. Additional stability is provided by TFIIB, 
which functions similarly to TFIIA [28]. Furthermore, TFIIB interacts 
with TFIIF to recruit a preformed TFIIF-RNAPII complex to the 
Chapter I - Introduction 
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promoter [29]. Finally TFIIE and TFIIH enter the complex. These two 
factors are involved in unwinding the DNA around the transcription 
start site [30,31]. TFIIH also contains a kinase activity, which can 
phosphorylate the C-t rminal domain (CTD) of the catalytic subunit of 
RNAPII [32]. CTD phosphorylation by TFIIH is thought to be 
important in promoter clearance and switching RNAPII to an 
elongation mode. This stepwise building of the preinitiation complex 
is based on in vitro studies. In contrast, yeast studies show that a so-
called holocomplex, where RNAPII is associated with several basal 
factors and proteins from the Mediator complex (discussed below) 
prior to recruitment to the promoter, exists in vivo [33]. 
 
1.1.4 The Mediator complex 
 
The Mediator complex was first characterized as TRAP and 
DRIP, cofactors for thyroid and vitamin D hormone receptors 
respectively [34,35]. The Mediator complex is known under an 
impressive number of different names and compositions such as 
TRAP, DRIP, ARC, SMCC, NAT, PC2, and CRSP (reviewed in 
[36,37]). This variation in composition might be linked to either the 
method of identification or the fact that larger complexes may be 
prone to dissociate during purification [38]. Alternatively, it may 
indicate that these Mediator complexes are modular in nature and that 
their composition varies according to promoter requirements [37]. 
Like CPB/p300 (discussed below) the Mediator complex can mediate 
contacts between gene specific factors and the basal transcription 
machinery. However, unlike CBP/p300, no HAT activity has yet been 
positively linked to any of the Mediator complexes. Nevertheless, 
most Mediator complexes have been shown to be coactivators, 
although some are also capable of repression of transcription [35,39-
43] 
 
1.1.5 Transcription factors 
 
Selective regulation of transcription requires the coordinated 
actions of the basal transcription machinery, general cofactors and 
gene specific transcription factors. These transcription factors 
generally consist of a sequence specific DNA binding domain and a 
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transcription activation domain (TAD). The distinction between these 
domains may not be as clear as it appears, since some transcription 
factors are still able to activate transcription after deletion of their 
activation domain. Their DNA binding motif might for instance act as 
a recruiting platform for cofactors [44-46], or, alternatively, impose 
conformational stress on the DNA, which might facilitate recruitment 
of additional DNA binding factors [47]. Transcription factors are 
classified by common motifs, usually their DNA binding domains. A 
wealth of structural data on DNA binding domains has been 
accumulated over the past years. Families of structurally conserved 
motifs have been defined including the helix-turn- li , leucine-zipper 
and zinc-finger motifs [48-52].  
 
1.1.6 Transcription activation domains 
 
Surprisingly little is known about the exact structure-function 
relations in the mechanisms by which TADs may work. A 
complicating factor in researching TADs is their lack of clearly 
conserved motifs. There is little sequence conservation in TADs. 
Nevertheless, a classification can be made based on general amino 
acid content. In this way acidic, serine/threonine rich, proline rich and 
glutamine rich TADs can be distinguished. Homopolymeric stretches 
of glutamine and proline fused to a Gal4 DNA binding domain have 
been shown to activate transcription in HeLa cells [53]. Glutamine and 
proline rich TADs have been shown to transactivate promoters from 
proximal positions, while being unable to activate a promoter from a 
distal enhancer. In contrast an cidic TAD could activate the promoter 
from both proximal and distal positions [54,55]. Therefore, it is likely 
that these different TAD types function via d stinct mechanisms. 
Furthermore, there is evidence that hydrophobic and acidic residues in 
TADs affect transcription at different moments in the process. In one 
study hydrophobic residues in the TAD of yeast heat shock factor 1 
(HSF-1) were shown to be important in stimulating elongation of a 
paused RNAPII, while the acidic residues were more important in 
stimulation initiation of transcription from the hsp70 gene [56]. 
Furthermore, it was shown that activation domains could function by 
either recruiting RNAPII or TFIID to the promoter [57]. Other studies 
show that acidic TADs may recruit SWI/SNF chromatin remodeling 
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complexes to a promoter [58-60]. Thus activation domains may serve 
to contact the basal transcription machinery or recruit cofactors. 
 
1.1.7 Structures of TADs 
 
Many TADs do not fold into a stable structure in solution. This 
observation led to the proposal that TADs may undergo an "induced 
fit" when they are brought in close proximity of their target. Indeed 
such induced fit mechanisms were shown for interaction of VP16 and 
p53 with hTAFII31 and MDM2 [61-63]. The TADs of VP16 and p53 
both contain FXXFF motifs (where X is any amino acid and F is a 
hydrophobic residue), which folds into an a-helix, when it is bound to 
hTAFII31. This induced fit places the phenylalinine and the two 
remaining hydrophobic residues on one side of the a-helix, presenting 
a hydrophobic patch to an interaction interface on hTAFII31, which 
could propagate the signal to the basal machinery. A similar motif is 
involved in the interaction of the activation domain of the transcription 
factor CREB and the KIX domain of coactivator CBP. Apart from a 
slight tendency to form a-helices, the phosphorylated kinase inducible 
domain (pKID) is unstructured in solution. Upon binding, pKID 
undergoes a coil to helix folding transition, wrapping into two a-
helices on a hydrophobic surface on the KIX domain [64,65]. This 
KIX domain on CBP interacts with the TADs of a number of other 
transcription factors, which contain hydrophobic patches similar to the 
FXXFF motif. For one of these, the interaction with c-Myb, studies 
indicate that its TAD employs a similar mechanism of binding as the 
pKID-KIX interaction [66]. 
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Figure 2 
A) Crystal structure of HPV-E2 TAD. 
B) Solution structure of the Zn-finger like TAD of ATF-2. 
 
 
It is not true that all TADs are structurally undefined. The 
crystal structure of the proteolytic core of the E2 activation domain of 
the human papillomavirus (HPV) has recently been determined [67]. 
The structure revealed a cashew shaped b-s eet framework, on which 
a slightly less well-defined glutamine-rich a-helix was docked (Fig. 
2a). This potentially flexible glutamine-rich a-helix may well function 
as a "classical" glutamine rich type TAD in contacting the basal 
machinery. A rationale for the high level of structure of this domain 
may be the dual function of the E2 activation domain in both 
transcription activation and stimulation of HPV DNA replication. A 
later study, which covered the intact full length E2 TAD, showed 
essentially the same fold, with the exception that the additional N-
terminal residues proved to be involved in dimer formation of the 
TAD [68]. This dimer formation may be important in regulating the 
switch between the E2 TAD's function in transcription activati  and 
replication. Another example of a structurally well-defined element in 
a TAD is the solution structure of ATF-2[69]. The structure of this 
TAD showed a completely unfolded C-terminal part, which does 
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contain FXXFF like patches, whiles the N-terminus folds into a 
typical zinc-finger structure (Fig. 2b, reviewed in [70]). This zinc-
finger may mediate protein-protein contacts with other transcriptio  
factors, which could mask or unmask the function of the remaining 
TAD. Further structural research of TADs in complex with their 
targets will be required to elucidate their exact functional mechanisms. 
 
1.1.8 Coactivators and corepressors 
 
Sequence specific transcription factors act in concert with 
cofactors. These factors either do not bind DNA themselves or do so 
in an aspecific manner, therefore, they need to be recruited to a 
promoter by transcription factors already bound to DNA. Cofactors act 
as bridging elements between transcription factors and the chromatin 
or the basal machinery. Many cofactors contain enzymatic activities 
such as HAT activity for coactivators and the reverse reaction (histone 
deacetylase (HDAC)) for corepressors. One such HAT containing
coactivator is the CREB binding protein CBP, which is often referred 
to in combination with closely related p300. Even though these two 
factors are highly similar, there is evidence that they are not 
completely functionally interchangeable. For instance, p300 lacks a 
PKC consensus site that is present in CBP, which needs to be 
phosphorylated to mediate AP-1 responsiveness [71]. Furthermore, 
genetic studies in mice indicate subtle differences between CPB and 
p300 knockouts [72,73], reviewed in [74]. CBP/p300 binds a variety 
of transcription factors and mediates contacts between these factors 
and the general transcription machinery [75-77]. In addition to 
histones, the acetyl transferase activity of CBP/p300 can also target 
other transcription factors such as p53 and Pit-1, which can modulate 
their DNA binding affinity [78,79]. Finally, CBP/p300 can mediate 
contacts with the Mediator complex. 
Analogous to stimulation by coactivators, corepressors can be 
recruited to a given promoter to silence its gene expression. Examples 
of corepressors are the nuclear receptor corepressor (NCoR) and the 
NuRD and Sin3 complexes. NCoR is found associated with 
unliganded or antagonist-bound nuclear hormone receptors [80], but 
can also associate with other types of transcription factors such as Pit-
1 [46], Rpx2 and Pbx [81], and CBF-1 [82]. Both NCoR and closely 
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related SMRT (silencing mediator for retinoid and thyroid receptors) 
function by recruiting and activating HDACs to target promoters [83], 
and there is evidence that they also interact with the basal transcription 
machinery [84,85]. These HDACs are either recruited directly, or as 
part of the Sin3 corepressor complex, which is involved in both NCoR 
and Mad-Max mediated repression [86,87]. The NuRD (nucleosome 
remodeling and deacetylase) corepressor complex contains both ATP-
dependent chromatin remodeling and HDAC activities, which appear 
to complement each other [88]. Furthermore, NuRD has recently been 
shown to contain  subunit that specifically recognizes methylated 
DNA, which would link epigenetic signaling to gene silencing [89].  
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Part II: Transcription regulation by Pit-1. 
 
1.2.1 Introduction 
 
The mammalian pituitary gland provides an excellent model 
system for the study of organogenesis and transcription regulation. 
The reason for this is that it features differentiation of six distinct cell 
types, in addition to highly restricted gene expression in these cell 
lineages. The pituitary gland is a composite organ consisting of two 
main lobes and a smaller intermediate lobe. These lobes are derived 
from two distinct embryonic tissues. The anterior and intermediate 
lobes, which make up the anterior pituitary or adenohypophysis, 
originate from an invagination in the oral ectoderm called Rathke's 
pouch. The posterior lobe or neurohypophysis is derived from the 
neural ectoderm. In the mature pituitary gland the neurohypophysis 
secretes anti-diuretic hormone (ADH) and oxytocin. The mature 
adenohypophysis produces a number of hormones from six different 
cell lineages. These are from dorsal to ventral: mela oopes ecreting 
melanin-stimulating hormone (MSH); corticotropes, 
adrenocorticotropin (ACTH); lactotropes, prolactin (PRL); 
somatotropes, growth hormone (GH); thyrotropes, thyroid stimulating 
hormone (TSH); and finally gonadotropes, which secrete luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH). A complex 
network of transcription factors tightly controls the embryonic 
development, differentiation of cell lineages and hormone production 
(reviewed in [90-93]). One of these transcription factors, called 
Pituitary transcription factor 1 (Pit-1), plays a central part in this 
network. The structural and functional aspects of Pit-1, a well as 
some transcription factors cooperating with Pit-1 ll be discussed in 
detail. 
 
1.2.2 Pituitary-specific transcription factor Pit-1 
 
Pit-1 (previously also known as Growth Hormone Fact r 1 
(GHF-1); now officially referred to as POU1F1) is specifically 
expressed in the pituitary gland [94]. Two alternative translation start 
sites cause the protein to be expressed in both a 31 and 33 kD form 
[95]. The protein consists of a N-terminal transcription activation 
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domain and a C-terminal DNA binding domain (Fig. 3) [96,97]. The 
DNA-binding domain of Pit-1 [98] is one of the founding members of 
the POU domain (POU is an acronym derived from the mammalian 
Pit-1, Oct-1 and Oct-2 and C. elegans Unc-86 factors) family of 
transcription factors ([99]reviewed in [100-103]), which will be 
discussed in detail below. 
 
 
 
 
 
 
Figure 3 
Pit-1 contains two DNA binding domains: the POU-specific and 
POU-homeodomain separated by a flexible linker. The N-terminal 
TAD can be alternatively spliced, giving rise to Pit-1b, which has a 
26 amino acids insert at position 48 and Pit-1T, which only has the 
C-terminal 14 amino acids of the b-insert at the same position. 
 
 
The Pit-1 gene was initially identified for its ability to bind and 
activate GH and PRL transcription [104,105]. Later it was found that 
Pit-1 also regulates the expression of the b-subunit of the thyroid-
stimulating hormone (TSHb) [106,107]. All three promoters contain a 
number of Pit-1 binding sites (Fig. 4). Extra-cellular signaling through 
both PKA and the Ras signaling pathways has been mapped to some 
of these binding sites [108,109]. 
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Figure 4 
Promoter structure of the rat PRL and GH and the human TSHb 
genes. Boxed areas indicate regions protected by Pit-1 in a DNaseI 
footprint. The PRL promoter contains a distal (D) as well as a 
proximal (P) promoter element for Pit-1. Both the 3P and 4P sites 
contain composite Pit-1/Ets-1 binding elements. The double T base 
insertion in GH-1 is marked. Data for PRL and GH promoters was 
taken from [95, 97] and for TSHb from [97]  
 
 
Two dwarf mouse strains have been described containing 
defects in the Pit-1 gene: the Snell and Jackson mouse strain, which 
have a substitution (W261C) in the DNA binding POU homeodomain 
and a deletion of a major part of the Pit-1 g ne due to a genetic 
rearrangement, respectively [110]. A third dwarf mouse strain, the 
Ames mouse, contained an intact Pit-1 gene, but lacked Pit-1 
expression due to a substitution (S83P) in the "Paired-lik  DNA 
binding domain of the Prophet of Pit-1 (Prop-1) gene. Prop-1 
expression precedes and is required for Pit-1 expression, but the exact 
mechanism involved remains unknown [111,112]. Studies of the 
Snell, Jackson and Ames mice showed that the secretion of GH, PRL 
and TSH is deficient in the absence of a functional Pit-1 gene product. 
Furthermore, these mice all showed hypoplastic pituitary glands, 
devoid of somatotropes, lactotropes and thyrotropes. Thus Pit-1 is an 
essential factor for both the differentiation of these three cell-types and 
the expression of the hormones they produce. Moreover, Pit-1 
regulates its own expression by binding to sites in the promoter region 
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of the Pit-1 gene [113,114]. In humans, mutations in Pit-1 are 
associated with Combined Pituitary Hormone Deficiency (CPHD) 
[115]. 
 
1.2.3 TAD and splice variants of Pit-1 
 
The TAD of Pit-1 does not seem to belong to any particular 
class of activation domains as mentioned above, although there is a 
high content of hydroxylated and proline residues. Dissection of the 
TAD shows an exon dependent functionality, with exon 1 (residues 1-
47) acting as a "generic" activation domain [96]. Exon 2 (residues 48-
72) contains an Y6Y6Y motif, which mediates contacts with the 
Estrogen receptor [116] and finally exon 3 (residues 73-147), which 
contains a proline rich and acidic region that is involved in synergistic 
with the thyroid receptor [117]. In this Y6Y6Y motif, any two of the 
three tyrosines are required for synergistic activation of the PRL 
promoter with Estrogen receptor. The exact spacing of the tyrosines 
does not seem to be important, as substitution with an Y5Y5Y motif 
from the human lymphoid specific transcription factor (hLEF-1) does 
not affect synergism. However, the interceding sequence also proves 
to be a determining factor, as substitution with an Y5Y5N motif from 
Ets-related SAP-1 results in a complete loss of synergism. This effect 
is likely due to the interceding residues in the SAP-1 Y5Y5N motif, as 
the Y6Y6N mutation in Pit-1 s ill shows wild-type synergism. Use of 
this Y6Y6Y required Pit-1 o bind as a monomer to the distal PRL-1D 
site [116]. 
Two alternative splice variants have been identified in the 
TAD of Pit-1: Pit-1b (also referred to as Pit-2) and Pit-1T. Both 
isoforms contain an insertion between exon 1 and 2 (Fig. 3). Pit-1T is 
an alternative splice variant that is exclusively expressed in the 
thyrotrope cell lineage [118]. The Pit-1T isoform is essentially the 
same as the Pit-1b splice variant, except that the Pit-1T insert 
corresponds to the C-terminal 14 amino acids of the b-ins rt (Fig. 3). 
Transfection analysis showed that while Pit-1, Pit-1b and Pit-1T alone 
were equally ineffective, a combination of Pit-1T and wild-type Pit-1 
was capable of an optimal activation of the TSHb promoter [119]. Pit-
1T mRNA levels were detected at about 2 % of wild-type Pit-1 levels. 
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Pit-1b contains an insertion of 26 amino acids between exon 1 
and 2 [120-122]. This alternative splicing of Pit-1 affects its ability to 
activate transcription. Pit-1b is more efficient in activating the PRL 
promoter when tested in non-pituitary cells, but less efficient in 
pituitary GH4 cells [123]. Furthermore, Pit-1b is a more potent 
mediator of PKA response in combination with Oct-1 [109]. Finally, 
Pit-1b represses Ras responsive signaling by inhibiting Pit-1/E s-1 
synergistic activation of the PRL promoter probably by direct 
interaction with Ets-1 and by recruiting an NCoR/mSin3 corepressor 
complex [124-126]. Two patches of hydrophobic residues within the 
b-domain were found to be important in this repression of Ras 
signaling [126]. The level of Pit-1b mRNA is about 14 % of wild-type 
[120,121], while the expression level of this alternatively spliced Pit-1 
is about 3 % of the wild-type Pit-1 [122]. Therefore, either Pit-1b is 
less stable, or less well transcribed than Pit-1. 
 
1.2.4 POU domains 
 
The POU domain factors are modular in nature, containing two 
independent helix-turn-helix folds separated by a flexible linker, 
which is of variable length. The N-terminal POU-specific (POUs) is a 
four-helix bundle, while the C-t rminal POU-homeodomain (POUhd) 
is a three-helix bundle (Fig. 5). Intriguingly, the in solution NMR 
structure of the Oct-1 POUs domain revealed that its fold is highly 
similar to the bacteriophage 434 and l repressors, even though the 
these domains share little sequence homology [127,128]. This 
structural conservation and modular nature of the POU domain family 
are clear examples of complexity arising from relatively simple 
precursor systems. Both the POUs and POUhd are independently 
capable of recognizing their target sites, albeit with reduced affinity 
compared to the full-length POU domain [129]. A mixture of 
untethered subdomains still shows a certain amount of cooperativity in 
binding its target site. However, tethering the two domains together 
via the flexible linker serves to increase the local concentration of 
either domain, once a promoter sequence is bound by one subdomain 
[130]. This allows one single POU domain to act as a heterodimer and 
increases the cooperative effect in binding the target site. 
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Figure 5 
Comparison of the human Pit-1 and Oct-1 sequences. Structural 
elements as they were encountered in the crystal structure are 
indicated below the sequences. The numbering corresponds to the 
constructs used in the crystal structure; the first residues of Pit-1 and 
Oct-1 correspond to residue 124 and 303 respectively in the full 
length protein. The dashed box at the end of helix 3 in the POUhd 
indicates the unfolded helix at the dimerization interface of Pit-1. 
 
 
A striking consequence of the modular structure and the 
variable linker lengths in the POU-domain transcription factors is the 
enormous flexibility in both sequence recognition and binding 
conformations. In the case of Pit-1 the recognition sequence varies 
around a loose consensus: (A/T)(A/T)TATNCAT (where N is any 
base). Pit-1 preferentially binds as a dimer, though it can also bind as a 
monomer [97,116,131]. In contrast, Oct-1, which is an ubiquitously 
expressed gene involved in activation of H2B [132], small nucleotide 
RNA [133] genes and viral replication (reviewed in [134]), primarily 
binds as a monomer, but can also act as a dimer [135,136]. 
Furthermore, even when binding as a monomer, Oct-1 can adopt 
several arrangements (Fig. 6) of the POUs and POUhd on the DNA, as 
was shown by photocrosslinking experiments [137]. 
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Figure 6 
Flexibility in arrangement of POUs+hd. The orientation of the 
subdomains is dictated by the DNA binding site. Pit-1 binds as a 
dimer to the palindromic Prl-1P site, while Oct-1 binds as a highly 
extended monomer to the Octamer sequence. Different orientations 
were shown by photocrosslinking Oct-1 to different DNA sites. 
 
1.2.5 Pit-1 and Oct-1 structure 
The structures of Oct-1 and Pit-1 bound to DNA have both 
been solved by X-ray crystallography (Fig. 7a) [131,135]. In the Oct-1 
cocrystal structure the POUs and POUhd bind to opposite sides of the 
DNA as a highly extended monomer. The third a-helix of the POUs 
docks in the major groove of the ATGC part of the octamer (5'-
ATGCAAAT-3') DNA element. The POUs makes several base 
specific hydrogen bo ds: Gln 44 forms a double hydrogen bond to A1, 
Thr 45 binds T2 and the complementary base to G3 (C'3) and finally, 
Arg 49 contacts G3 and G'4. One hydrophobic residue (Leu 55) 
contacts the methyl group of T5 (Fig. 7b). Sequence specific contacts 
are complemented by a number of contacts to the phosphate-backbone 
by residues throughout the rest of the POUs. Likewise, the third a-
helix of the POUhd docks in the major groove of the AAAT part of 
the octamer, where it makes one hydrogen bonding (Asn 51 to A7) 
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and two hydrophobic (Val 47 makes a van der Waals contact to T8 
and Cys 50 docks between T'9 and T'10) contacts. The flexible link r 
is disordered and therefore not visible in the cocrystal structure. 
However, the C-terminal part of the linker, towards the POUhd is 
located in the minor groove between the ATGC and AAAT parts of 
the octamer sequence, where Arg 5 of the POUhd contacts A5 of the 
AAAT half site. Interestingly, Leu 55 of the POUs contacts the 
complementary T (T'5) to this base. Such dual contacts might explain 
the cooperative effect of binding of the two subdomains to DNA. 
 
 
 
 
Figure 7a 
Crystal structures of Pit-1 and Oct-1. Pit-1 binds as a dimer to the 
palindromic Prl-1P site. The flexible linkers between the POUs and 
POUhd are not visible. 
 
The Pit-1 cocrystal structure shows Pit-1 bound as a dimer to a 
palindromic site (5'-CCTCATGTATATACATGAGG-3') derived 
from the PRL-1P promoter element. The structure reveals a dramatic 
rearrangement of the POUs and POUhd subunits. Instead of binding 
opposite sides of the DNA, the POUs and POUhd now bind 
perpendicular to each other on the DNA. In addition, the POUs have 
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flipped their orientation compared to the Oct-1 cocrystal structure (see 
also Fig. 7a). In spite of these differences, the DNA contacts of the 
subdomains are very similar to those observed in the Oct-1 structure 
(Fig. 7b). The POUs in this structure recognize an ATAC half site, 
while the POUhd bind to a TCAT half site. Again, the POUs 
contribute base specific contacts through Gln 44, Thr 45 and Arg 49, 
but now additional hydrogen bonds are seen with Ser 43 and Arg 49 to 
T4/T'9 and G3/G'10, respectively. The POUhd also s ows two new 
contacts (Arg 46 to T-2/ '14 and Gln 54 to A1/A'12) in addition to 
those that were also seen in the Oct-1 stru ure. It is possible that the 
slightly higher resolution (2.3 Å vs. 3.0 Å) of the Pit-1 cocrys al 
allowed for the identification of these extra contacts. 
The fact that Pit-1 is bound as a dimer in the cocrystal structure 
and the absence of the flexible linker in these studies, allows for two 
possible combinations of linkages. One of these would put the two 
subdomains of one monomer on opp site sites of the DNA, much like 
the arrangement in the Oct-1 cocrystal structure. The other 
combination would put the two monomers on more or less the same 
face of the DNA. The fist arrangement would require a highly 
extended (and thus more rigid) linker structure, while the second 
arrangement would allow for a more relaxed conformation of the 
linker. To discriminate between these two possibilities, Jacobson t al 
assayed the dimidiation ability of several linker deletion mutants of 
Pit-1. These studies showed that Pit-1 dimerization was tolerant to 3 
and 5 amino acid deletions from the linker, confirming the relaxed 
linker conformation in the second monomer arrangement [131]. 
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Figure 7b 
Protein-DNA contacts as they occur in both the Pit-1 and the Oct-1 
crystal structures. Numbering corresponds to the one used in Fig. 7. 
Dashed arrows depict non-polar contacts. 
 
 
The dimer interface is located at the C-terminal part of the 
POUhd, which docks on the surface formed by the loop between the 
second and third a-helix and the N-terminal part of the first a-helix of 
the POUs of the adjacent monomer (Fig. 8). Direct hydrogen bonds 
are formed between the backbone amide protons from the POUhd 
residues Val 59 and Lys 60 with the carboxyl groups from Leu 53 and 
55 on the POUs. Two additional hydrogen bonds are formed between 
the side chain of POUhd Arg 58 and the backbone and side chain 
carboxyl groups of POUs Gln 54. Furthermore, POUhd Val 59 docks 
in a hydrophobic pocket formed by the POUs residues Met 6, Leu 9, 
Leu 53 and Phe 57. Finally, POUhd Lys 60 might form a salt bridge 
with Glu 10 of the POUs. Intriguingly, one of the most frequent Pit-1 
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mutations associated with CPHD maps to the dimer interface of the 
POUhd. This mutation (R271W) is likely to affect dimerization of Pit-
1 on DNA, as Jacobson et al showed deletion of the last three residues 
(Arg 58, Val 59 and Lys 60) from the POUhd impaired dimerization 
on three separate probes. The R271W mutation results in a dominant 
negative phenotype [138,139], which implies that dimerization of Pit-
1 is essential for its in vivo function. 
 
 
 
 
Figure 8 
The dimerization interface between the POUs of one monomer and 
the C-terminus of the POUhd of the other monomer. Arg 58 of the 
POUhd makes a double hydrogen bond to the backbone and side 
chain carboxyl group of Gln 54. The backbone amide protons from 
POUhd Val 59 and Lys 60 hydrogen bond to the backbone carboxyl 
group from POUs Leu 53 and 55. The side chain of POUhd Val 59 
docks in a hydrophobic pocket on the POUs surface. Finally, POUhd 
Lys 60 may form a salt bridge with POUs Glu 10. 
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1.2.6 Allosteric effects 
 
 The high level of flexibility in DNA binding of POU 
transcription factors allows for an intriguing level of promoter control. 
In a recent study by Scully et al, the differential activation of the PRL 
and GH genes in somatotropes and lactotropes was investigated [140]. 
It was found that substitution of the most proximal Pit-1 binding site 
in the GH promoter (GH-1) with the corresponding site from the PRL 
promoter (Prl-1P) resulted in expression from the mutant GH 
promoter in lactotropes. The finding that a single Pit-1 binding site 
was responsible for repression of GH expression in lactotropes 
prompted Scully et al to cocrystallize Pit-1 using the GH-1 or Prl-1P 
site. The resulting cocrystal structures showed Pit-1 bound as a dimer 
to both sites, with the same contacts and overall arrangement as was 
found on the palindromic site (discussed above). However, due to a 
two base pair insertion between the half sites of the GH-1 element, the 
spacing between the POUs and POUhd of each monomer was 
increased from 4 bp to 6 bp. This resulted in binding of each Pit-1
monomer to the same side, rather than to perpendicular faces of the 
DNA (Fig. 9). 
The authors show, by chromatin immunoprecipitations (ChIP) 
and transgenic mouse studies, that this alternative conformation of the 
Pit-1 dimer preferentially recruits a NCoR containing corepressor 
complex to the GH promoter in lactotropes. Thus, a model is proposed 
wherein PRL and GH gene control in somatotropes and lactotropes is 
regulated by the balance between coactivator (CBP) and corepressor 
(NCoR) complex recruitment by Pit-1. A previous study, in which a 
Pit-1 mutant (E254A; which corresponds to E41A in Fig. 5) showed 
an increased affinity for NCoR, while DNA and CBP binding were 
unaffected, corroborates this model [46]. This point mutant proves that 
CBP and NCoR use different interaction surfaces on the POU domain, 
which can therefore be masked or unmasked by the orientation of the 
Pit-1 POU domain on the DNA. What the study of Scully et al does 
not show is why the same GH-1 binding site leads to activation of GH 
in somatotropes. Most likely, a cell-specific factor either overrides 
NCoR mediated repression in somatotropes or enhances this 
repression in lactotropes. Such an enhancer of repression might exist 
in lactotropes, as mutation of the -161/-146 promoter element of the 
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rat PRL promoter resulted in GH expression in lactotropes [140]. 
Similar allosteric effects were show for Oct-1 bound as a dimer to 
PORE (5'-ATTTGAAATGCAAAT-3') or MORE (5'-
ATGCATATGCAT-3'). The PORE-bound Oct-1 dimer was able to 
recruit coactivator OBF-1, while in the MORE-bound dimer the 
interaction domain for OBF-1 was buried in the dimerization domain 
[136]. 
 
 
 
 
Figure 9 
Allosteric effects in Pit-1 binding. The insertion of two T bases 
results in a different arrangement of the Pit-1 dimer on DNA 
(adapted from ref. 140). Both crystal structures were aligned to show 
the same orientation of the POUhd from monoer 1 (top right). To 
the right a schematic representation of the orientation of each dimer 
on its DNA sequence. 
 
 
1.2.7 Pit-1 phosphorylation 
 
 In response to the cell cycle or homeostatic signaling, Pit-1 c n 
be phosphorylated at two positions: S115 and T220[141,142]. 
Phosphorylation of T220 seems to have a negative effect on DNA 
binding in general, though the effects may differ from minimal to a 10 
fold decrease in affinity, depending on the exact sequence of each 
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binding site [141-143]. The corresponding residue in Oct-1 (S385) is 
also phosphorylated in a cell cycle dependent manner, which strongly 
inhibits its DNA binding affinity [144]. A structural rationale for the 
less dramatic, site-dependent effects of phosphorylation at T220 in Pit-
1 can be found in the crystal structure of Pit-1 bound to the 
palindromic site. Contrary to S385 in the Oct-1 crystal structure, T220 
is not in close proximity (3.6 vs. 6,7 Å) to any phosphate group. 
Therefore phosphorylation at T220 is likely to have less dramatic or 
more context dependent effects on DNA binding than the 
corresponding modification in Oct-1 [131,135]. The in vivo relevance 
of Pit-1 phosphorylation is as yet unclear. Mutating S115, T220 and a 
minor phosphorylation site at T219 to alanines did not affect Pit-1 
transactivation capabilities on the GH and PRL promoters [145] or its 
ability to cooperate with Ets-1[125]. Furthermore, while 
phosphorylation of Pit-1 was highly increased by Thyrotropin 
releasing hormone (THR), this was not the cause of an increased PRL 
expression, since the same stimulation by THR was observed in the 
presence of agents that blocked Pit-1 phosphorylation [146]. Further 
research is required to assess the role of phosphorylation of Pit-1 in 
vivo. 
 
1.2.8 Pit-1 interacting factors 
 
 Pit-1 acts in concert with a number of other transcription 
factors to confer gene specific activation or repression. This may 
involve direct protein-protein interactions, or DNA mediated contacts. 
Figure 10 shows an overview of all protein-protein interactions with 
Pit-1 reported thus far. Recruitment of coactivat r and corepressor 
complexes [46,140], the interaction with the Estrogen receptor (ER) 
[116] and Thyroid receptor (TR) [117]have been discussed above. A 
third nuclear receptor, the vitamin D receptor (VDR) was shown to 
interact with Pit-1 hrough the POUhd [147]. P-OTX or Pituitary 
homeobox 1 (Ptx-1) was identified in a yeast two-hybrid screen using 
the Pit-1 TAD as bait [148]. Further research showed that P-OTX / 
Ptx-1 is involved in the activation of several pituitary-specific 
promoters and that it can act in synergy with Pit-1 [149,150]. P-Lim is 
a homeobox containing protein that is expressed in the pituitary and 
can also act in synergy with Pit-1. Direct protein-protein interaction 
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involves the DNA-binding homeobox of both proteins [151]. A similar 
interaction exists with Oct-1: both a weak in solution protein-protein 
interaction and a heterodimerization through the POU domains of both 
proteins on the PRL-1P promoter element [152]. Heterodimerization 
with Oct-1 on one DNA site would allow the simultaneous use of 
functionally distinct pathways of transcription activation, such as 
recruitment of CBP by Pit-1 and OBF-1 and VP-16 by Oct-1. The 
interactions of Pit-1 with GATA-2 and Ets-1 will be discussed in 
detail below, as they are studied in this thesis.
 
 
 
 
 
Figure 10 
Overview of proteins with a reported physical interaction with Pit-1. T e 
dashed lines indicate the mapped region of each interaction. 
 
 
1.2.9 GATA-2 
 
 Zinc-finger protein GATA-2 is a member of the GATA-
binding family of transcription regulators. The GATA factors are 
required for a number of developmental processes, such as the normal 
hematopoietic development [153-156]). Two CX2C-X17-CNAC Zn-
finger motifs regulate DNA binding in the GATA proteins. Both Zn-
fingers will recognize the consensus (A/T)GATA(A/G) motif [157], 
but DNA binding affinity depends on the presence or absence of 
clusters of basic amino acids adjacent to each finger [158]. Thus in 
GATA-1, where the N-terminal Zn-finger lacks this basic region, the 
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C-terminal finger provides most of the binding affinity, while the N-
terminal finger stabilizes the DNA binding [159,160]. 
 A factor binding along with Pit-1 to the P1 region of the TSHb 
promoter was identified as GATA-2. Further investigation showed 
that Pit-1 and GATA-2 could synergistically activate the TSHb 
promoter and that the intact binding sites of both factors were required 
for this response [161]. A detailed study by Dasen et al revealed that, 
along with Pit-1, GATA-2 is an essential player in the cell-fate 
determination in the anterior pituitary [162]. Dasen et al showed that 
GATA-2 is present in a ventral to dorsal gradient and that at the 
highest level of this gradient, Pit-1 expression is restricted. 
Furthermore, Pit-1 could bind GATA-2 in a DNA-independent 
fashion, thus preventing DNA binding by GATA-2. This protein-
protein interaction required the POUhd of Pit-1 and the C-terminal Zn-
finger, along with a stretch of basic residues, of GATA-2. Pit-1 
mediated restriction of DNA binding was effective, unless a promoter 
contained both a Pit-1 and a GATA-2 site, such as in the case in the 
TSHb promoter. Thus, in the absence of Pit-1, regulation of 
transcription by GATA-2 causes cells to terminally differentiate into 
gonadotropes. When both Pit-1 and GATA-2 are present, restriction of 
DNA binding by Pit-1 allows only for Pit-1 / GATA-2 composite 
promoter elements to be activated, causing differentiation into 
thyrotropes and not gonadotropes. Finally, in the absence of GATA-2, 
Pit-1 regulation causes precursor cells to differentiate into 
somatotropes or lactotropes. 
 
1.2.10 Ets-1 
 
 Ets-1 was originally identified as v-ets, a transduced part of a 
fusion protein with v-myb, which was expressed by the E26 (Ets is 
derived from E-twenty-six specific) acute avian leukemia retrovirus 
[163]. The cellular counterpart turned out to be a prototypical member 
of an entire family of transcription factors containing the Ets domain 
(reviewed in [164,165]). The Ets domain in Ets-1 recognizes a 
GGA(A/T) motif [166]. Both the free and DNA bound structures of 
the Ets-1 domain, which is defined as a "winged helix-turn- li " 
DNA binding domain, have been solved by NMR (Fig. 11) [167, 68]. 
DNA binding of Ets-1 is regulated by sequences both N- and C-
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terminal of the DNA binding domain, which fold into auto-inhibitory 
modules [167,169]. Upon DNA binding, conformational changes are 
observed in the auto-inhibitory modules, as indicated by altered 
protease sensitivity [170,171]. Inhibition of DNA binding can be 
relieved by cooperative binding with another factor [172,173] r 
reinforced by phosphorylation of sequences directly upstream of the 
N-terminal auto-inhibitory domain [174]. 
 The N-terminal region of Ets-1 contains a separately folding a-
helical domain called the Pointed (PNT) domain. The structure of this 
domain, which is shared by a number of Ets family members, was 
solved by NMR spectroscopy [175]. Located at the N-terminus of the 
PNT domain is a threonine (T38), which is targeted by MAP kinase 
upon Ras activation (reviewed in [176]). The exact mechanism by 
which Ras-mediated phosphorylation enhances transcription activation 
by Ets-1 remains enigmatic. The NMR study by Slupsky et al did not 
reveal any structural rearrangements or changes in protein dynamics 
upon phosphorylation [175]. Therefore, enhanced activity of MAP 
kinase phosphorylated Ets-1 is likely due to increased binding of a 
secondary factor. 
 
 
 
 
Figure 11 
A) Solution structure of the DNA binding domain of Ets-1. The 
“winged helix-turn-helix” domain feature three a-helices scaffolded 
by four b-sheets. The DNA recognition helix is indicated. 
B) Solution structure of the Ets-domain bound to DNA. 
C) Solution structure of the N-terminal Pointed domain of Ets-1. 
Threonine 38, which is targeted by Ras-mediated MAP kinase 
phosphorylation, is indicated. 
Chapter I - Introduction 
 38
 Ets-1 is involved in T-cell differentiation [177-179] and is 
widely expressed during mouse embryogenesis [180]. In addition Ets-
1 was implicated as a cellular integrator of Ras activation of the PRL 
promoter [181]. Further research showed that Ras activation mapped 
to a composite element in the footprint-4 (FP4) region at -212/-189 of 
the PRL promoter. This composite site contains binding sites for Pit-1 
and Ets-1. Contrary to Ets-1, Pit-1 is not a target for Ras induced 
phosphorylation. Nevertheless, the presence of Pit-1 is required to 
elicit full response to Ras activation of the composite element 
[108,182]. In HeLa non-pituitary cells and independent of Ras 
signaling, Ets-1 and Pit-1 still functionally cooperate to achieve a 6 
fold synergistic activation of the PRL promoter. The highly related 
GH promoter does not exhibit this response, since it does not contain 
any Pit-1/Ets-1 composite elements. Hence, the functional cooperation 
of Ets-1 and Pit-1 is a mechanism to confer promoter specificity on the 
PRL promoter. Aside from their functional interaction, Pit-1 and Ets-1 
also physically interact in solution. This interaction requires the 
POUhd of Pit-1 and a part of the activation domain (located between 
the PNT and the Ets domain), which is specif c for Ets-1 [124,125]. 
The interaction of Ets-1 with the alternative splice variant Pit-1b has 
been discussed above. A detailed study on the interaction of the 
POUhd of Pit-1 and Ets-1 is presented in chapter 3 of this thesis. 
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1.3 Outline of this thesis 
 
 This thesis focuses on the structural and functional aspects of 
the pituitary specific transcription factor Pit-1. Pit-1 is an essential 
regulator for the expression of pituitary hormones such as growth 
hormone. Mutations in Pit-1 can therefore lead to combined pituitary 
hormone deficiency (CPHD) in humans. Chapter II describes a clinical 
case study of a patient with CPHD caused by two novel mutations in 
the Pit-1 gene. Biochemical characterization showed that both 
mutations result in a non-functional Pit-1 protein by abrogating its 
DNA binding activity. Pit-1 s involved in the activation of 
transcription of several different promoters. Regulation of the 
specificity of Pit-1 transactivation on these promoters requires 
interaction with other cellular transcription factors. One such factor is 
the transcription factor Ets-1, which interacts with Pit-1 in solution 
and regulates transcription on the PRL promoter through a composite 
Pit-1/Ets-1 binding site. In chapter III, the interacting region on Ets-1 
is mapped to a stretch of about 70 amino acids. This Ets-1 region is 
used in NMR experiments to define the exact residues on the Pit-1 
POUhd required for the interaction. Functional implications on the 
regulation of Pit-1/Ets-1 association are discussed. Chapter IV 
describes NMR studies on the DNA binding ability of the Pit-1 
POUhd both alone and in complex with the interacting region of Ets-1. 
Finally, chapter V investigates a putative in vivo function of an 
interaction that was found between the Pit-1 TAD and the CR3 region 
of adenoviral transcription regulator E1A 13S splice variant. 
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Chapter 2
2.1 Abstract 
 
The POU-homeodomain containing transcriptional 
activator POU1F1, formerly called Pit1 or GHF-1 (here referred 
to as Pit-1), is required for the embryologic determination and 
postnatal secretory function of the growth hormone (GH), 
prolactin (PRL) and thyroid-stimulating hormone (TSH) 
producing cells in the anterior pituitary. Several mutations in the 
gene encoding Pit-1 have been described, resulting in a syndrome 
of combined pituitary hormone deficiency (CPHD) involving these 
three hormones. Most of the patients with this phenotype have 
either a dominant negative mutation in codon 271 (R271W) or are 
homozygous for a recessive mutation in the Pit-1 gene; so far only 
one case has been reported with compound heterozygosity for two 
point mutations. Here, we describe a boy with severe deficiencies 
of GH, PRL and TSH who turned out to have compound 
heterozygosity for two novel point mutations in the Pit-1 g ne: a 
one-base pair deletion frame shift mutation (747delA), the first 
one described thus far in this gene, which leads to a nonfunctional 
truncated protein lacking the entire DNA-recognition helix of the 
POU-homeodomain, and a missense mutation in the C-terminal 
end of the fourth a -helix of the POU-specific domain (W193R) 
which causes a 500-fold reduction in the ability to bind to DNA 
and to activate transcription. 
 
2.2 Introduction 
 
The anterior pituitary-specific transcription factor POU1F1, as 
the human homologue of Pit1/GHF1 is now officially called, belongs 
to the family of POU-domain proteins and plays a critical role in the 
embryonic differentiation and survival of the somatotrope, lactotrope 
and thyrotrope cell lineages [183,184]. Its expression is required for 
the transcriptional activation of, among others, the growth hormone 
(GH), prolactin (PRL) and thyrotropin (TSHâ) genes [185]. 
The DNA-binding POU-domain of Pit-1 is located in the C-
terminal part of the molecule (amino acids 119-273). It consists of a 
60 amino acids (aa) POU-homeodomain (POUhd) and a 75 aa POU-
specific (POUs) domain, connected by a 15 aa flexible linker [99]. 
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Both domains contribute to the specific and high-affinity binding of 
the Pit-1 molecule to its recognition sequence, (A/T)(A/T)TTATNCAT 
[97]. The crystal structure of the Pit-1 POU-domain bound to DNA 
shows that both subdomains contain helix-turn-  motifs and form 
a dimer [131]. DNA-binding by Pit-1, as well as interaction with other 
nuclear proteins, are required for specific transactivation of its target 
genes [46]. 
Two strains of dwarf mice have been shown to harbor 
structural defects in the Pit-1 gene resulting in combined pituitary 
hormone deficiency (CPHD) with pituitary hypoplasia and absence of 
somatotropes, lactotropes and thyrotropes. The Snell dwarf mouse 
carries a G®T missense mutation at nucleotide 783 of the POUhd, 
which replaces a tryptophan residue at position 261 by a cysteine 
(W261C). The Jackson dwarf mice, on the other hand, have a genomic 
rearrangement resulting in a truncated Pit-1 protein, which has lost its 
DNA-binding capacity [110]. To date, twelve mutations (9 missense, 2 
nonsense and 1 deletion) have been described in the human Pit-1 gene 
[138,139,186-196]. Two of these are located in the transactivation 
domain, six in POUs and four in POUhd. They result in a partial or 
total deficiency of GH and PRL and, to a variable deg ee, of TSH. In 
some patients anterior pituitary hypoplasia is evident on radiographic 
imaging of the hypothalamic-pitu tary area. Dependent on their 
localization in the Pit-1 coding sequence, the mutations may either 
interfere with DNA-binding or with the transactivation process. Most 
are transmitted as an autosomal recessive trait, but four of them, two 
in the transactivation domain (P14L, P24L) and the other two located 
at the borders of the POUhd (K216E, R271W), appear to result in a 
dominant-negative phenotype with a highly variable level of 
penetrance. 
In this report we describe a boy with CPHD who turned out to 
be a compound heterozygote for two novel mutations in the Pit-1 
gene. Both parents, who have a normal phenotype, harbor these 
mutations in the eterozygous state. The maternal allele carries a 
missense mutation in the POUs domain resulting in complete 
abolishment of DNA-binding. The paternal allele harbors a one base 
pair deletion frame shift mutation, the first described thus far in the 
Pit-1 gene, resulting in a truncated Pit-1 molecule lacking helix 3 of 
the POUhd. 
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2.3 Materials and Methods 
 
2.3.1 Mutational analysis of the Pit-1 gene 
mRNA was isolated from Epstein-Barr virus transformed 
lymphocytic cell lines from the proband, his parents and his brother. 
This mRNA was reverse transcribed and the Pit-1 POU-domain 
amplified by nested PCR, essentially using the procedure and the 
oligonucleotide primers as described by Pfäffle et al.[186]. The PCR-
products were sequenced bidirectionally using the Amplicycle 
sequencing kit (Perkin-Elmer). Genomic DNA was isolated from the 
lymphocytic cell lines and all six Pit-1 exons were amplified 
separately by PCR, using the pairs of oligonucleotide primers 
corresponding to the intron/exon boundaries as described by Ohta et 
al.[189], with modifications essentially as described by Pellegrini-
Bouiller et al.[194]. The PCR-products were analyzed by SSCP 
(Genephor, Amersham-Pharmacia Biotech) and used for direct 
sequencing. 
 
2.3.2 Plasmids 
For the construction of Pit-1 OU-domain expression vectors, 
wild-type and mutant cDNA carrying the W193R mutation in the Pit-1 
POUs-domain were obtained by RT-PC  as described above. The 
PCR-products were ligated into the original TA Cloning vector, pCR 
2.1 (Invitrogen) and transformed to E. coli DH5a. Subsequently, both 
cDNAs were cloned into an NdeI/BamHI digested pET15b expression 
vector (Novagen) yielding His6-tagged Pit-1 POU-domain open 
reading frames (ORFs). The DNA sequenc was hecked by dideoxy-
chain termination sequencing (Invitrogen). 
The GH320-luc and PRL DE/P-luc reporter/luciferase 
constructs, containing the rGH promoter sequence and the rPRL distal 
enhancer and promoter sequence, respectively, were reported 
previously [186] and were a kind gift of Dr. Rosenfeld, Howard 
Hughes Medical Institute, University of California, San Diego, La 
Jolla, California. For construction of a TSHb-luc reporter/luciferase 
construct the GH320 insert was replaced by a 280 bp insert derived 
from the human TSHb promoter (nt -206 to +74, ref. [197]) containing 
three putative Pit-1 binding sites [143]. This fragment was obtained by 
one round of PCR (36 cycles of 45 sec at 95°C, 1 min at 57°C and 2 
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min at 72°C) on 100 ng of genomic DNA as template, using 200 pmol 
each of the oligonucleotide primers 5'-GAGAGGAAAATGCATGC 
TTT-3' and 5'-TATCATTTCACAGAGCCTTC-3'. The fragment was 
cloned into the pCRII-TOPO TA cloning vector (Invitrogen) and 
sequenced. 
For use in the transfection assays, pCMV-Pit-1 expression 
plasmids were constructed as follows. Pit-1 ild-type and mutant 
cDNAs, encompassing the entire Pit-1 coding sequence, were obtained 
by a one-side nested RT-PCR using 2 different upstream primers (5'-
TGATTTGGGGAGCAGCGGTT-3' and 5'-CTACTCTCTTGTGGG 
AATGAG-3', respectively) and one downstream primer (5'-ATACA
ATAGAAAACTTTATCTGCACTC-3') in two consecutive rounds of 
PCR, each consisting of 36 cycles of 30 sec at 95°C, 1 min at 58°C, 2 
min at 72°C. We constructed a total of four different pCMV 
constructs: pCMV-Pit-1 wt cDNA, pCMV-Pit-1 cDNA containing the 
W193R mutation, pCMV-Pit-1 cDNA containing the 747delA 
mutation, and a pCMV vector without insert to be used as a control 
effector plasmid. All constructs were cloned into pTargeT (Promega) 
and sequenced bidirectionally. An RSV-bGAL construct was used as 
an internal control for transfection efficiency in transient transfection 
experiments, as has been described elsewhere [198]. 
 
2.3.3 Protein expression and purification 
Wild-type and W193R-mutant Pit-1 POU-domain expression 
vectors were transformed to strain BL21 (pLYS). Strains containing 
the wild-type and mutant vectors were grown in 1 liter cultures at 
37°C and room temperature, respectively. At O.D.600= 0.5 expression 
was induced by adding 1 ml of 1 M IPTG. Wild-type Pit-1 POU-
domain expression was continued for 3 h at 37°C, while W193R Pit-
1POU was expressed overnight at room temperature. Cells were 
pelleted, resuspended in 20 ml sonification buffer (50 mM NaPO4, 300 
mM NaCl, 0.5 mM PMSF, 1 mg/ml aprotinin and 10 mM b-
mercaptoethanol) and lysed by freeze-thawing and mild sonification. 
Insoluble components were removed by centrifugation in a SW41 
rotor at 35.000 rpm for 45 min. Wild-type and W193R Pit-1 POU-
domain proteins were partially purified on Ni-NTA agarose (Qiagen) 
columns. Samples were estimated to be approximately 70-80% pure 
on a Coomassie stained gel. 
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2.3.4 Gel retardation assay 
For preparation of the probe, the GH320-luciferase construct 
described above was digested by HindIII and end-labeled using the 
Klenow fragment of DNA-polymerase I (Pharmacia) and a-32P dCTP 
(Amersham, 10 mCi/ml, 3000 Ci/mmol), followed by XhoI digestion. 
The resulting 300 bp fragment containing the rGH-promoter was 
purified by polyacrylamide gel electrophoresis. Pit-1 dilutions were 
made in 50 mM Tris-HCl (pH 7.5), 1 mM EDTA (pH 8.0), 100 mM 
NaCl, 10% glycerol and 10 mM b-mercaptoethanol. Approximately 2 
fmol DNA was incubated with Pit-1 dilutions in a reaction mixture 
containing 20 mM HEPES-KOH (pH 7.5), 100 mM NaCl, 1 mM 
EDTA (pH 8.0), 1mM dithiothreitol, 0.025% NP-40, 1 mg poly dIdC 
competitor DNA and 4% Ficoll for 30 min at room temperature. Prior 
to loading, 2 ml of 0.02% bromophenol blue and 0.02% xylene cyanol 
was added. The samples were run on a 6% polyacrylamide gel 
containing 0.01% NP-40, at 4°C for 3 h at 30 mA. The gel was dried 
and the DNA was visualized by autoradiography. 
 
2.3.5 DNaseI footprint assay  
Pit-1 dilutions were prepared as above. Approximately 10 fmol 
of DNA was incubated with Pit-1 as in the gel retardation assay, with 
an additional 1 mg of bovine serum albumin, 10 mM MgCl2 and 3 mM 
CaCl2 per reaction. After 30 min at room temperature, samples were 
incubated with 0.01 unit of DNaseI for 5 min. Reactions were 
quenched by adding 11 ml of 10 mg/ml herring sperm DNA, 200 mM 
NaAc (pH 8.0) and 75 mM EDTA (pH 8.0). The DNA was purified by 
phenol/chloroform extraction prior to ethanol precipitation. Dried 
samples were resuspended in loading buffer (80% formamide, 0.1 % 
bromophenol blue and 0.1% xylene cyanol) and loaded on a 6% 
polyacrylamide sequencing gel (8M urea). The gel was run for 1.5 
hour at 30 mA, dried and the DNA was visualized by autoradiography. 
 
2.3.6 Co-transfection assays 
The adenovirus transformed human embryonic kidney (HEK) 
293 cells [199] were cultured as a monolayer in DMEM containing 
10% FCS, and 3.5 mmol L-Glutamine, 100 U of penicillin and 100 mg
of streptomycin per ml. Cells were transfected when approximately 
50% confluent using the calcium phosphate-DNA co-precipitation 
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technique [200] in N,N,bis[2-hydroxyethyl]-2-aminoethanesulfonic 
acid (BES, Sigma) buffered saline. Each 25 cm2 flask was transfected 
with 3 mg of reporter plasmid and 500 ng of pRSV-lacZ in order to 
normalize for transfection efficiency. The optimal quantity of wt-P -1 
effector plasmid to be used in combination with each reporter 
construct was determined by titration in such a way that the 
transfection potency was still in the linear range; for the hTSHb and 
the rPRL reporter constructs a total of 500 ng of effector were used, 
whereas for the rGH reporter 25 ng sufficed. Four hours after adding 
the precipitate to the cells, the medium was changed and the cells were 
harvested 22 hours thereafter. Luciferase and b-galactosidase assays 
were performed as described [198,201]. Luciferase data were divided 
by the galactosidase activity to correct for transfection effici ncy. All 
transfections were performed in duplicate in at least three separate 
experiments. 
 
2.4 Results 
 
2.4.1 Clinical evaluation 
Our patient, a boy, was born in India and came to the 
Netherlands at the age of 4 months. He is the second childof unrelate  
healthy parents with normal stature; he has a healthy and normally 
growing brother. As dictated by the Dutch neonatal screening program 
for congenital hypothyroidism (CH) he was screened as yet for CH 
shortly after arrival in our country; a heel puncture T4 of only 8 nmol/l 
was found, together with an undetectable TSH and a normal TBG 
concentration. Physical examination at the age of 4.5 months revealed 
typical signs of CH, with a low nasal bridge, macroglossia, facial 
myxedema and wide-op n fontanels. He exhibited generalized 
hypotonia, slight peripheral myxedema, constipation and hypothermia. 
His length at that point was 51 cm (-9 SD), body weight 4100 g. 
The first laboratory results showed the combination of a very 
low FT4 (2.8 pmol/l) and TSH concentration (<0.1 mU/l), low IGF-1 
(5 ng/ml) and IGFBP3 (0.3 mg/l) and undetectable prolactin 
concentrations (<1 mg/l). Plasma cortisol (580 nmol/l) and ACTH 
concentrations (53 ng/l) were normal and testosterone was appropriate 
for age (2.3 nmol/l). Following an intravenous injection of 30 mg of 
thyrotropin releasing hormone (TRH) all TSH levels remained <0.05 
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mU/l and prolactin remained <1.0 mg/l. ACTH and cortisol plasma 
concentrations rose normally after 40 mg of CRH intravenously. After 
reaching euthyroidism with appropriate thyroxine treatment an 
arginine provocation test was performed. Basal GH levels were 
undetectable and remained < 1 mU/l following an intravenous infusion 
of 0.5 mg/kg arginine. An MRI-scan of the hypothalamic-pituitary 
region showed a hypoplastic anterior pituitary but otherwise normal 
anatomy (Fig. 1). The boy was started on daily growth hormone 
injections to which he responded well; he is now 3.5 years of age and 
has attained a height of 98.3 cm (-1.1 SD). He is in good health and 
shows no signs of neurodevelopmental delay. 
 
 
 
 
Figure 1 
MRI of the proband’s hypothalamic-pituitary region, showing marked 
hypoplasia of the anterior pituitary (arrowhead). 
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2.4.2 Molecular studies: Two novel mutations in the Pit-1 gene 
Sequence analysis of lymphocyte-derived Pit-1 cDNA 
encompassing the POUs and POUhd regions [186] revealed 
heterozygosity in the proband and his mother for a missense mutation 
at position 577 in exon 4, a T®C transition that changed amino acid 
193 from Trp to Arg (W193R). Since the mother had a normal 
phenotype as well as a normal hormonal p ofile, a dominant negative 
effect of this mutation was considered unlikely. Therefore, further 
investigation aimed at identifying an additional mutation in the 
proband’s paternal Pit-1 allele. To this end, direct genomic sequencing 
of all six exons of the Pit-1 gene from both parents, the proband and 
his brother was performed, which confirmed the heterozygosity in 
exon 4 in the proband and his mother, and identified an additional 
heterozygosity in the DNA of the proband and his father for a one-
basepair deletion at position 747 in exon 6, codon 249 (747delA, the A 
nucleotide of the ATG codon of the primary translation product being 
taken as position +1) (Fig. 2). The shift in the reading frame resulting 
from this deletion changes the subsequent codon from Glu to Asn and 
introduces a translational stop codon immediately thereafter. 
Thus, our patient is heterozygous for a missense mutation in 
exon 4 (W193R) inherited from the mother and a one-basepair 
deletion frameshift mutation in exon 6 (747delA) inherited from the 
father. The effect of the frameshift mutation, a loss of helix 3 of 
POUhd, is very similar to the E250X nonsense mutation described by 
Irie et al.[195], which in the homozygous state led to CPHD in their 
patient. Since the W193R missense mutation had not been described 
before, the properties of the resulting mutant Pit-1 protein with respect 
to DNA-binding and transactivation were further analyzed. 
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Figure 2 
Genomic DNA sequence analysis of (from left to right) the father, the 
mother, the proband’ brother and the proband. Top panel: sequence 
gel of exon 4, maternal missense mutation. Bottom panel: sequence 
gel of exon 6, paternal one base pair deletion frameshift mutation. 
The changes in the sequence are depicted to the right. 
 
 
2.4.3 W193R binds DNA with ~500-fold reduced affinity in vitro
DNA binding affinity of the wild-type and W193R Pit-1 POU-
domain were tested in vitro, using the Pit-1 binding site of the rGH-
promoter as probe. As shown in figure 3, bacterially expressed wild-
type Pit-1 POU-domain bound with high affinity, whereas binding of 
the W193R Pit-1 POU-domain to the same site was ~500-fold 
reduced. Similar results were obtained on the prolactin (PRL) 
proximal enhancer (data not shown). Residual DNA binding affinity 
can be attributed to the POUhd, which is still intact in the W193R 
mutant. 
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Figure 3 
Bandshift assay on the GH-promoter region. Approximately 2 fmol of 
DNA was incubated with 50, 75, 100, 125 and 150 pg. of wild-type 
Pit-1 and with 100, 1000, 10000, 20000 and 40000 pg. of W193R 
mutant Pit-1. 
 
 
2.4.4 W193R is unable to protect its site in a DNaseI footprint assay 
The apparent lack of binding of the W193R mutant in the gel 
retardation assays might have been caused by the formation of mutant 
Pit-1/DNA-complexes that are too unstable to enter the gel. Moreover, 
the use of high concentrations of wild-type Pit-1 resulted in higher 
order complexes (data not shown), which might either be caused by 
binding of the protein to cryptic binding sites in the probe or by 
'piggy-back' binding of Pit-1 o one site. To test these possibilities we 
performed DNaseI footprint assays. As can be seen in figure 4, the 
wild-type Pit-1 POU-domain was able to protect a region of 17 
basepairs of the rGH-promoter, whereas the W193R mutant did not 
show any protection at all, even at high protein concentrations. We 
can therefore conclude that DNA binding of the W193R mutant is 
seriously impaired, which explains its lack of transactivation 
capability. 
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Figure 4 
DNaseI footprint assay on the GH-promoter region. Approximately 
10 fmol of DNA was incubated with 100, 200 and 400 pg. of wild-
type Pit-1 and with 20000, 40000 and 60000 pg. of W193R mutant 
Pit-1. A Maxam-Gilbert T-sequencing lane was added to localize the 
binding site. 
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2.4.5 W193R and 747delA are unable to activate transcription  
in vivo. 
To assay the in vivo activity of the W193R and 747delA 
mutants, we transfected constructs expressing various combinations of 
wild-type and/or mutant Pit-1 to human embryonic kidney 293 
(HEK293) cells. Wild-type Pit-1 strongly activated the rPRL promoter 
(30x) and to a lesser extent the rGH (3x) and the hTSHb (3x) 
promoter. As shown in figure 5, when either one of the mutant 
expression constructs was transfected together with the wild-type
construct, the transactivation potency declined to approximately 60-
70% of the wild-type level. This situation reflects the genetic 
background of the parents and the results are consistent with the fact 
that neither parent showed an abnormal phenotype. When both 
mutants were co-transfected, transactivation dropped to background 
level. From these results we conclude that neither mutant is able to 
activate transcription, which explains the minimal levels of GH, PRL 
and TSH found in the patient. 
 
 
 
Figure 5 
Stimulation of transcription on the rGH, rPRL and hTSHb-promoter 
by wild-type Pit-1, W193R and 747delA mutants and combinations 
thereof. 
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2.5 Discussion 
The clinical presentation in this patient is remarkable. The 
majority of patients with a Pit-1 defect present with growth failure and 
are diagnosed as having GH-deficiency, whereas less than half present 
with hypothyroidism as the first clinical manifestation [202]. Our 
patient clearly belongs to the latter category: he was detected at the 
age of 4.2 months by the Dutch neonatal CH-screening program. This 
was only possible because the CH-screening in the Netherlands is 
primarily a T4 screening, with a subsequent determination of TSH and 
TBG in heel puncture blood [203]. Furthermore, the program dictates 
that children under the age of six months, coming to the Netherlands 
and not having been screened before, be screened upon arrival in our 
country. The patient was found to be severely hypothyroid: his heel 
puncture T4 level was only 8 nmol/l (normally >100 nmol/l) and heel 
puncture TSH was undetectably low. However, some thyroxine 
production must have existed in the first months postnatally, since 
when he was tested psychologically at the age of 2 years no 
abnormalities were found. Among patients with Pit-1 def ciency, the 
degree of hypothyroidism, both in terms of plasma thyroid hormone 
and TSH levels and of response to TRH, is far more variable than that 
of GH and PRL deficiency [204]. Patients also show phenotypic 
differences with respect to the degree of anterior pituitary hypoplasia. 
Pfäffle [202] already speculated upon differences in the mode of 
interaction of Pit-1 with the GH and PRL promoters on one hand and 
the TSHb promoter on the other, but how these differences relate to 
the nature of the mutations is still largely unknown. 
Our patient turned out to be a compound heterozygote for two 
novel mutations in the Pit-1 gene. The one base pair deletion mutation 
in the POUhd at position 747 (747delA), transmitted by the paternal 
allele, is the first frameshift mutation in the Pit-1 gene described so 
far. The frameshift causes a change in the codon following E249 fr m 
Glu to Asn and introduces a translational stop codon immediately 
thereafter. This mutation is therefore almost identical to the E250X 
nonsense mutation described by Irie et al.[195]. In either case the 
translational stop codon is located at the C-terminal end of helix 2 of 
the POUhd. In the homozygous state, they will undoubtedly res lt in a 
severe loss of DNA binding since the entire helix 3 with the DNA-
recognition domain of POUhd is deleted. 
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Figure 6 
Crystal structure of Pit-1 complexed to DNA, as determined by 
Jacobsen et al. For the sake of clarity, only one Pit-1 molecule is 
shown. 
A) The W193 residue, located in the hydrophobic core of the POU-
specific domain is highlighted. 
B) Direct result of a stop codon at position 251: the entire DNA-
recognition helix of the POU homeodomain is deleted. These 
pictures were generated using the Molscript program [207] 
 
The T®C missense mutation at position 577, conferred by the 
maternal allele, predicts a tryptophan-to-arginine substitution at codon 
193 located in the C-terminal end of the fourth a-helix of the POUs 
domain. The natural occurrence of this W193R mutation has not been 
reported before, but it has been reported in a yeast in vivo screening 
model for DNA-binding negative Pit-1 mutants [205], in which it 
demonstrated only 2% of the DNA-binding activity of the wild-type 
protein. Figure 6 shows the crystal structure of Pit-1 [131], wi h 
tryptophan 193 highlighted. W193 is one of the amino acid residues 
that make up the hydrophobic core of the POUs domain. The a-helix 
harboring this codon can be considered to be a structural helix, since it 
does not contact the DNA directly. However, changing W193 to an 
arginine introduces a positively charged residue into the hydrophobic 
core. Our bandshift and footprint assays show that the W193R POU-
domain is no longer able to bind to DNA with sufficient affinity, 
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probably due to improper protein folding of the POUs domain. As a 
result, the mutant W193R POU-domain is unable to activate 
transcription, as shown in our transient transfection experiments. The 
residual Pit-1 activity of approximately 60-70% in the heterozygous 
state as measured in our transient transfection assays can be expected 
to ensure a normal phenotype, as others have observed a clinically 
recessive phenotype with residual activities of approximately 50% in 
comparable assays [196]. 
In conclusion, in our patient neither allele of th  Pit-1 gene 
yields a functional gene product, which explains his severe combined 
pituitary hormone deficiency and pituitary hypoplasia. These two 
novel recessive mutations bring the number of naturally occurring Pit-
1 mutations to fourteen, among which 10 missense, 2 nonsense, 1 
deletion and, finally, 1 frameshift mutation (Figure 7). Study of other 
patients with CPHD will undoubtedly result in a further increase of 
this number of mutations in Pit-1 or n related genes such as PROP-1 
[112,206]. However, since a significant number of patients still turn 
out to have CPHD in spite of normal Pit-1 nd PROP-1 coding 
sequences (R. Pfäffle, personal communication), the molecular 
unraveling of these defects remains a challenge for the future.
 
 
 
 
 
Figure 7 
Presently known naturally occurring mutations in the Pit-1 molecule. 
The mutations described in this paper are heavily boxed. 
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  "There's a significant amount of voodoo involved..." 
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3.1 Abstract 
 
Understanding of the molecular basis of protein-protein 
interactions is essential in order to comprehend the molecular 
machinery that governs complex processes like transcription and 
replication. Even though a wealth of data has been generated i  
the fields of crystallography and NMR spectroscopy, this 
understanding is still limited. Here we describe a detailed NMR 
study of the interaction between the POU-domain protein Pit-1 
and Ets-1, a member of the ETS family of transcription factors. 
Pit-1 and Ets-1 can associate in solution and synergistically 
activate the prolactin (PRL) promoter by and binding to a 
composite response element in the PRL promoter. We mapped the 
minimal region of Ets-1 required for the interaction with the Pit-1 
POU-homeodomain. By using hetero nuclear single quantum 
coherence (HSQC) titration experiments, we were able to map the 
exact residues on the POU-homeodomain that are involved in the 
interaction with this minimal Ets-1 interaction domain. Using our 
NMR data, we generated point mutants in the POU-homeodomain 
and tested their effect on the interaction with Ets-1. 
 
3.2 Introduction 
 
The POU-domain transcription factor Pit-1 is one of the key 
regulators of gene expression in the anterior pituitary gland. The 
presence of Pit-1 is an essential and determining factor in the 
differentiation of the somatotrope, lactotrope and thyrotrope cell 
lineages. Furthermore, in these cell lineages, Pit-1 is required for the 
expression of the growth hormone (GH), prolactin (PRL) and 
thyrotropin (TSHb) genes, respectively [92,184,208]. The expression 
of these genes is restricted to their respective cell lineages. However, 
since Pit-1 is present in all three cell types, cooperation with other 
transcription factors is required in orderto achieve selective 
expression. Indeed, recent data show that depending on the promoter 
context and cell type, Pit-1 can act as either enhancer or repressor of 
transcription by selective recruitment of coactivator or corepressor 
complexes [140], reviewed in [209]. 
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One example of a promoter-specific Pit-1 interaction is the 
Ras-activated expression of the PRL promoter. Ras-d pendent 
activation of the PRL promoter is achieved through Ets-1 and requires 
the interaction of Pit-1 with Ets-1. Ras responsive Ets-1 i  one of the 
founding members of the ETS family of transcription factors, which is 
defined by a highly conserved winged helix-turn helix DNA binding 
domain [167]. Previously, it was found that Ras activation of the PRL 
promoter required the presence of a Pit-1/Ets-1 composite element in 
the PRL promoter [108,210]. Furthermore, we have shown that Pit-1 
and Ets-1 form a DNA-independent complex in solution and that both 
factors displayed strong synergy in activation of the PRL promoter in 
a reconstituted, Ras-independent expression system in HeLa cells 
[124]. The physical association of these proteins involved the POU-
homeodomain of Pit-1 and a part of the region III activation domain of 
Ets-1 located between the N-terminal Pointed domain and the C-
terminal ETS DNA binding domain [124,125]. 
In the present study, we further define the minimal r gio  of 
Ets-1 required for the in solution interaction with the Pit-1 
homeodomain. Both this minimal interacting region on Ets-1 a d the 
Pit-1 homeodomain were capable of interacting with one another 
outside the context of the full-l ngth proteins. Using NMR 
spectroscopy, we performed a fine mapping of the exact residues on 
the surface of the POU homeodomain of Pit-1 that are in contact with 
the minimal interacting region of Ets-1. Thi  mapping allowed us to 
define a novel interaction domain that may apply for other POU 
homeodomain interactions. Our approach presents an interesting 
possibility to probe weaker protein-protein interactions.  
 
3.3 Materials and methods 
 
3.3.1 Plasmid Construction 
The wild-type pGex Pit-1 (199-291) expression vector has 
been described [145]. The mutant homeodomain fragments of rat Pit-1 
(T220D, K226A, K226D, E254A, W261F, R268A, K270A and 
L288A) were generated by overlap extension polymerase chain 
amplification utilizing primers purchased from Gibco Life 
Technologies, Inc. Mutant primers were used in combination with 5' 
and 3' Pit-1 (199 -291) primers that incorporate a Not I site to facilitate 
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subcloning. The amplified DNA was initially cloned into pCR 2.1 
(Invitrogen) and then subcloned into the Not I site of pGexDFGK. The 
sequences of the primers are as follows: 5' Pit-1 (199-291)-
GCGGCCGCCAGG TCG AGCTTTGTACAAT, 3' Pit-1 (199-291)-
GCGGCCGCTTATCTGCACTCAAGATGCTC. 5' T220D-GAGGACAGATATCAGTATCGC, 
3' T220D-GATACTGATATCTGTCCTCCGT, 5' K226A-GCCGCTGCCGATGCTTTGG 
AGA, 3' K226A-AAAGCATCGGCAGCGGCGATAC, 5' K226D-GCCGCTGACGATGC 
TTTGGAG, 3' K226D-AAGCATCGTCAGCGGCGATAC, 5' E254A-TGAATCTCGCCA 
AAGAAGTAGTAAG, 3' E254A-TACTTCTTTGGCGAGATTCAATTC, 5' W261F-
GTAAGAGTGTTCTTTTGCAACCG, 3' W261F-GTTGCAAAAGAACACTCTTACTAC, 5' 
R268A-AAGGCAGGCCGAAAAACGGGT, 3' R268A-CGTTTTTCGGCCTGCCTTCGG, 5' 
K270A-AGAGAGAAGCCCGGGTGAAAAC, 3' K270A-CACCCGGGCTTCTCTCT 
GCC, 3' L228A-GAGCGGCCGCTTATCTGCACTCGGCATGCTCCTTTG. 
The Pit-1 expression plasmids, pRc.935Pit1wt FLAG and 
pRc.935Pit1A3 FLAG, encoding wild-type and a Pit-1 
phosphorylation mutant, respectively [145], were provided by Dr. 
Fred Schaufele (University of California, San Francisco). Plasmid 
pSG5c-Ets-1 encodes the p68 chicken Ets-1 under control of the SV40 
early promoter. This construct as well as the series of C-terminal 
deletions of Ets-1, pSG5c-Ets-1D3-1 through pSG5c-Ets-1D3-10 
[211], and the GST- Ets-1 fusion construct, pGex p68 Ets-1 full 
length, were provided by Dr. Bohdan Wasylyk (I.G.B.M.C., Illkirch, 
France). pGex Ets-1 (190-257) was generated by combining the 
amino-terminus of pSG5 Ets-1D5-4 (AA 190-485) with the C-
terminus of pSG5 Ets-1D3-8 (AA 1-257) using a common restriction 
site. The resulting construct was subcloned into pGexDFGK or 
pRSETA. The pSG5 Ets-1 BPV-1, BPV-2, and BPV-3 constructs 
contain p68 c-Ets-1 with 26 amino acid scanning block mutations of 
Ets-1 in the region of amino acids 190-257. These mutations were 
made utilizing overlap extension PCR to amplify mutated fragments 
of Ets-1 from nucleotides 401 to 1054. The fragments were cloned 
into PCR 2.1 and subcloned into pSG5 Ets-1 by digesting at internal 
Bgl II and Afl III sites. PCR primers utilized are listed below: BPV-1 
S-CTAAATGTGCCAGCAATGTGATTCCTGCTAAAGAAGACCCTTATGCCCCCTCTGAGTTC 
TCTG, BPV-1 AS-TTGCTGGCACATTTAGTTGCAGGAGACTCTATATAGCGATAGGTGTC 
CACTCCGTTTGCTGGG, BPV-2 S-CTAAATGTGCCAGCAATGTGATTCCTGCTAAAGAAG 
ACCCTTATGCCTCGG, BPV-2 AS-TTGCTGGCACATTTAGTTGCAGGAGACTCTATATAG 
CGATAGGTGTCGTGCTCGATGCCATAA, BPV-3 S-CTAAATGTGCCAGCAATGTGATTCC 
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TGCTAAAGAAGACCCTTATGCCGTCCAGACGGACTCCC, BPV-3 AS-TTGCTGGCACATT 
TAGTTGCAGGAGACTCTATATAGCGATAGGTGTCGGTCTGGTAGGACTCT, p68 Ets-1 
401 S-TGAAGGGAGTGGATTTCC, p68 Ets-1 1054 AS-CATAGTCCTTGAAGGTGC. 
The fragment encoding residues 213-289 of the human Pit-1 
ORF was cloned into an NdeI/BamHI digested pET15b expression 
vector (Novagen), yielding His6-tagged Pit-1 POU-homeodomain. The 
fragment encoding residues 190-257 or 235-304 of the human Ets-1 
protein was cloned into an NdeI/BamHI digested pET15b- erived 
vector. This vector was obtained by using the primers 
5'GGAAATACTTACCCATGG GCGATAAAATT3' and 5'ATATGAGATCCCATGGGTAC 
CTTGTCATCGTC3' purchased from Amersham Biotech (Pharmacia) to 
clone the ORF for thioredoxin from the pTrxFus vector (Invitrogen) 
into the NcoI site of pET-15b. The resulting vector codes for a N-
terminal thioredoxin tag in addition to the His6-tag. All DNA 
sequences were checked by cycle sequencing on an automated 
sequencer (ABI-Prism). 
 
3.3.2 GST pulldown Assays 
Recombinant fusion proteins were prepared from bacterial 
extracts and bound to glutathione- Sepharose CL-4B (Amersham 
Pharmacia Biotech) as previously described [125]. Ets-1 and Pit-1 
fusions were also supplemented with 10 or 1 mM dithiothreitol, 
respectively. Protein concentration was measured by the Bio-Rad 
assay (Bio-Rad). Bound protein was analyzed by SDS-polyacrylamide 
gel electrophoresis and Coomassie Blue Staining. [35S]-labeled 
proteins were synthesized and labeled with [35S]-methionine (NEN 
Life Science Products), using the TNT coupled transcription-
translation reticulocyte lysate system with T7 polymerase, according 
to the manufacturer’s protocol (Promega, Madison, WI). Pull down 
assays were performed in dilute solution using equal amounts (5 or 20 
mg) of GST fusion proteins bound to 20 ml of glutathione sepharose 
beads in the presence of 50 mg/ml ethidium bromide as previously 
described [125]. The [35S]-labeled proteins were eluted from the beads 
by boiling in SDS sample buffer and analyzed by SDS-pol acrylamide 
gel electrophoresis and autoradiography. Bands were quantified using 
a Molecular Dynamics Phosphorimager with Imagequant software and 
normalized for input of equal amounts of fusion protein based on 
densitometry of the Coomassie Blue stained gels. 
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3.3.3 Protein purification 
The Pit-1 homeodomain was expressed in BL21 (DE3) 
bacteria grown on synthetic medium (10.38 g/l K2HPO4· 3H2O, 4.38 
g/l KH2PO4, 50 mg/l MgSO4· 7H2O, 7 mg/l (NH4)2FeSO4· 6H2O, 10 
mg/l thiamin, 0.05 mg/ml ampicillin) containing 0.5 g/l 15NH4Cl as the 
sole nitrogen source and 5 g/l 12C- lucose or 1 g/l 13C-glucose as the 
sole carbon source. Bacteria were grown to an OD600 of 1.0 and 
induced by addition of IPTG to a final concentration of 1 mM. After 
2.5 hours the cells were harvested and lysed in 50 mM NaxHyPO4 (pH 
6.5), 500 mM NaCl, 10% glycerol, 0.01% NP-40, 0.5 mM PMSF, 1 
mg/ml aprotinin, 10 mM b-mercaptoethanol and 10 mg/ml lysozyme. 
The lysate was cleared by centrifugation at 30,000 x g for 45 minutes 
at 4°C and loaded on a Ni-NTA column (Qiagen) equilibrated in 50 
mM NaxHyPO4 (pH 6.5), 200 mM NaCl, 10% glycerol, 20 mM 
imidazole and 10 mM b-mercaptoethanol. After washing, the protein 
was eluted in a linear gradient from 20-400 mM imidazole. Peak 
fractions were pooled, diluted to 100 mM NaCl and loaded on a SP-
sepharose column (Pharmacia) equilibrated in 50 mM NaxHyPO4 (pH 
6.5), 100 mM NaCl, 10% glycerol and 10 mM b- ercaptoethanol. 
The protein was eluted in a linear gradient from 100-1000 mM NaCl. 
Peak fractions were pooled and concentrated to approximately 1 mM 
in an Amicon stirred ultrafiltration cell (Millipore) using a 3 kD cut-
off filter. The buffer was exchanged to a final 50 mM NaxHyPO4 (pH 
5.5), 100 mM NaCl and 1 mM dithiotreitol (DTT). The thioredoxin-
his6-Ets-1 (190-257) or (235-304) were expressed in BL21 (DE3) 
bacteria grown on Luria Broth (LB) medium containing 0.05 mg/ml 
ampicillin. Expression and lysis were done as above, with the 
exception that induction took place at an OD600 of 0.6. The cleared 
lysate was bound to Ni-NTA material (Qiagen) equilibrated in 30 mM 
TRIS-HCL (pH 8.0), 200 mM NaCl, 10% glycerol, 20 mM imidazole 
and 10 mM b-mercaptoethanol by rotating for 1 hour at 4°C. The 
material was washed and block eluted with 400 mM imidazole. Eluted 
protein was further purified on a Superdex 75 gelfiltration column 
(Pharmacia) equilibrated in 30 mM TRIS-HCL (pH 8.0), 200 mM 
NaCl, 10% glycerol, 20 mM imidazole and 10 mM b-
mercaptoethanol. Peak fractions were subjected to thrombin cleavage 
by adding 2.5 mM CaCl2 and 100 units of thrombin from bovine 
plasma (Sigma) and incubating at RT for 2 hours. Cleaved protein was 
Chapter 3
 65
applied to a Ni- TA column (Qiagen). Ets-1 (190-257) or Ets-1 (235-
304) were present in the flow through, while thioredoxin- s6 
remained bound to the column. After a second run on the Superdex 75 
gelfiltration column (Pharmacia), the sample was concentrated and 
washed as described above. 
 
3.3.4 NMR Spectroscopy 
NMR experiments were carried out at 305 K (32°C) on Varian 
UnityInova 500 and 750 spectrometers. The protein concentration was 
1 mM in all experiments, 10% D2O was added to obtain a lock signal. 
Spectra were processed u ing NMRPipe [212] and analyzed using 
NMRVIEW [213]. Protein-protein titrations were carried out by 
repeated addition of Ets-1 (235-304) to a 15N-labeled Pit-1 
homeodomain and recording a 750 MHz 1H15N-HSQC spectrum after 
each addition. The sample was concentrated in an Amicon stirred 
ultrafiltration cell to keep the total volume around 500 ml. 
 
3.4 Results 
 
3.4.1 Mapping of the minimal interacting region on Ets-1 
 In order to identify the minimal region of Ets-1 required for 
interaction with Pit-1, we used 3' deletions of p68 chicken Ets-1 a d 
tested their ability to interact with GST-bound Pit-1 homeodomain 
(residues 199-2 1). As shown in figure 1B, 35S-labeled in vitro 
translated full-length Ets-1 is capable of binding to the Pit-1 
homeodomain (POUhd). Deletion of the C-terminal auto inhibitory 
region caused a 50% decrease in binding, likely caused by changes in 
the overall structure of the ETS domain, since subsequent deletions up 
to D3-4 increased binding affinity almost to wild-type level. The most 
carboxy-teminal Ets-1 deletion that retained Pit-1 binding was 
truncated at AA 257 (D3-8), indicating that AA 257-485 do not 
contribute to binding. However, deletion of 68 AA to position AA 189 
(D3-9) results in almost complete loss of Pit-1 binding and further 
deletion to AA 71 results in complete loss of binding activity. Thus, 
binding affinity for Pit-1 dropped drastically with deletions in the Ets-
1 RIII activation domain. 
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Figure 1 
Residues 190-257 of the Ets-1 RIII are necessary and sufficient to 
bind Pit-1. Equal amounts of in vitro translated [35S]- labeled proteins 
were bound to 5 mg of GST control or fusion proteins as described in 
materials and methods. Nonspecific binding to GST alone was 
subtracted from total binding and specific binding is expressed as % 
of input. Data are representative of three separate experiments. 
A) Schematic representation of Ets-1 and the constructs used in this 
study. 
B) Deletion mapping of binding of [35S]-p68 Ets-1 and Ets-1 
truncations D3-1 (AA450), D3-2 (AA412), D3-3 (AA390), D3-4 
(AA368), D3-5 (AA358), D3-6 (AA314), D3-7 (AA275), D3-8 (AA257), 
D3-9 (AA189), and D3-10 (AA71) to the POUhd; 10% of input, 
nonspecific and specific binding of [35S]-Ets-1 and deletion 
constructs are shown. 
C) The 190-257 region of Ets-1 is sufficient to bind in vitro translated 
[35S]-Pit-1. 
D) Linker scanning mutations identify Ets-1 AA 232-257 as the site 
of the most robust interaction with the POUhd. 
 
 
 Combined with previous results using 5' deletions to map the
interaction [124], this study defines the region of Ets-1 required for 
Pit-1 binding as part of the RIII activation domain, between residues 
190-257. To confirm that this region is sufficient, we expressed it as a 
GST-fusion. As shown in figure 1D, GST-Ets (190-257) could indeed 
bind Pit-1. Since neither the N-t rminal Pointed domain, nor the C-
terminal Ets-1 DNA-binding domain are required for the interaction, 
we can consider the 190-257 region as an independent binding domain 
within Ets-1. Therefore we chose to study the interaction of the 
POUhd with this minimal Ets-1 region, outside the context of the full-
length protein. 
 
3.4.2 NMR studies on the interacting residues in POUhd 
The chemical shifts of amide protons are highly sensitive to the 
binding of an interaction partner or ligand [214], or conformational 
changes in the protein [215]. Using this sensitivity, we investigated 
which amide protons of the 15N-labeled POUhd (residues 213-289) 
show changes in chemical shift in a 1H-15N correlated HSQC (hetero-
nuclear single quantum coherence) experiment upon addition of the 
unlabeled interaction domain of Ets-1 (residues 190-257). These 
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amide protons should be in close proximity to any side chain 
contacted by Ets-1. This approach would allow us to map which 
residues on POUhd are directly or indirectly involved in the 
interaction, without interference from the spectrum of Ets-1 (190-257). 
15N-labeled POUhd (residues 213-289) was expressed and 
purified as described in materials and methods. The 1H-15N-correlated 
HSQC spectrum recorded at 750 MHz showed well-dispersed signals, 
indicative of an ordered structure (figure 2A). Unfortunately, addition 
of any amount of Ets-1 (190-257) resulted in heavy precipitation and 
only minor changes in the 1H-15N-correlated HSQC spectrum of the 
POUhd. Attempts to remedy this problem by changing the pH and salt 
concentration did not provide satisfying results (data not shown). 
Linker-scanning experiments using insertions of the 26 AA sequence 
from the BPV L-1 capsid with an AU1 epitope along the Ets-1 (190-
257) region, mapped the most robust interaction with Pit-1 to the C-
terminal one third of the (190-257) region (figure 1D). Therefore we 
chose to use an Ets-1 construct that contained the C-terminal one third 
of the (190-257) region and extend it towards the C-terminus of Ets-1. 
The resulting (235- 04) is less hydrophobic in nature and indeed did 
not precipitate when added to the POUhd at pH 5.5 and 100 mM 
NaCl. 
 
 
 
Figure 2 
NMR analysis of the Ets-1 (190-260) interaction with the POUhd. 
A) The 1H-15N-correlated HSQC spectrum of POUhd (residues 213-
289) recorded at 750 MHz. The selected regions show 
superimposed spectra of free POUhd (black) and after the addition 
0.5 (gray) and 1 (white) molar equivalent of Ets-1 (235-304). The 
chemical shift values of some N-H signals (like T220, I221 and 
S222) change drastically upon addition of Ets-1, while others are 
moderately (R268) or hardly (K216, K255, E269) affected. 
B) Combined 1H-15N chemical shift perturbations mapped against 
the secondary structure of the POUhd. The values are the mean of 
two independent experiments and were calculated as Euclidian 
distances between peaks: DdNH=((Dd15N)2 + (Dd1H)2)1/2, where Dd15N 
and Dd1H denote the nitrogen and proton shifts in Hz, respectively. 
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As shown in the zoomed regions in figure 2A, a number of 
backbone amide protons display a change in chemical shift that is 
dependent on the amount of Ets-1 (235-304) added, while others are 
unaffected. The changes in the spectra were specific for Ets-1, as an
equimolar amount of the unrelated bovine serum albumin (BSA) did 
not result in any changes in chemical shift (data not shown). Since 
these backbone amides were the same as the ones displaying very 
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minor shifts after the addition of Ets-1 (190-257), we are confident 
that the majority of the interaction indeed resides in the overlapping 
region between our two constructs. The gradual, concentr tion 
dependent changes in chemical shift resonances in the presence of Ets-
1 indicate that the two proteins are in fast exchange on the NMR 
timescale. We were able to add Ets-1 (235-304) up to about equimolar 
level to POUhd. Further addition of protein resulted in heavy 
precipitation without any further change in chemical shifts. The fact 
that the signal intensity of the HSQC spectrum was not severely 
affected indicates that this precipitate is probably Ets-1 (235-304). 
Indeed, SDS-PAGE analysis of the pr cipitate showed that it 
contained mostly Ets-1 (235-304) (data not shown). Therefore, we are 
unable to add more than an equimolar amount of Ets-1 (235-304). 
Given the moderate changes in chemical shift, the two peptides may 
not yet have reached saturation st te of binding. This indicates that, at 
the conditions used to record the spectra, the KD for  minimal 
domain complex is in the micro to millimolar range. 
In order to identify the amide protons involved in the 
interaction, we expressed and purified 13C/15N- ouble labeled POUhd. 
Using triple resonance experiments (HNCA, HN(CO)CA, CBCANH 
and CBCA(CO)NH), coupled with 3D-15N-NOESY HSQC, we could 
assign the resonance frequencies of nearly all backbone amide protons 
(table I). In the 3D-15N-NOESY HSQC, we were able to track the a-
helices, as they were resolved in the crystal structure of the Pit-1 POU 
domain bound to DNA [131]. In addition, we found that the POUhd 
C-terminal (272-289) tail is rather unstructured in solution with few 
inter-residual NOEs and sharp signals in the 1H-15N HSQC. Our 
assignment allowed us to plot the difference in chemical shift in the 
absence and presence of Ets-1 (235-304) against the primary structure 
(fig. 2B). 
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Table I 
Backbone assignment for the Pit-1 POUhd residues 213-289. ND: 
not determined. 
 
 
The most drastic changes in chemical shifts of backbone 
amides are located around threonines 219 and 220 in the N-terminal 
part of the homeodomain. Interestingly, these threonines can be 
phosphorylated in vivo [142]. The level of chemical shift change 
along the first helix of the homeodomain appears to have a periodicity 
of three residues, indicating that only one side of this helix is in close 
proximity to Ets-1. This region forms a bridge between the N-terminal 
threonines and a less sharply defined region at the C-terminus of the 
DNA binding helix of the homeodomain, where the amide protons are 
moderately affected. The flexible C-terminus outside the 
homeodomain was hardly affected, except for H287 and L288 at the 
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very end of the protein. A surprisingly large change in chemical shift 
occurred on the amide proton of W261. In the crystal structure, the 
side chain of this residue is almost comple ely buried in the 
hydrophobic core of the homeodomain and is therefore unlikely to be 
involved in contacting Ets-1. There is, however, a hydrophobic pocket 
around the amide proton of W261, formed by V257, V258, I221 and 
part of the tryptophan side chain itself in which Ets-1 might dock. The 
only other amide protons, besides the W261 backbone amide, 
bordering this hydrophobic pocket are the backbone amides of V258, 
I221 and T219. The amide protons of all these residues shift 
drastically upon addition of Ets-1. Moving away from this 
hydrophobic pocket, on the other side of the W261 backbone amide, 
the shifts in the amide protons become less pronounced. Specifically, 
the Ne-H of the tryptophan side chain is moderately affected, while the 
backbone amide of F262 is hardly affected. 
 
3.4.3 Mutational analysis 
In previous studies, using GST-pulldown assays, deletion of 
either the N- or C-terminal half of the homeodomain resulted in a 50 
% decrease in pull-down efficiency [125]. This suggested that there is 
more than one region for the interaction with Ets-1 located on the 
POUhd. The NMR results suggest binding of Ets-1 might take place 
around T219/T220, in the hydrophobic pocket next to W261 and at the 
extreme C-terminus of the POUhd, possibly with stabilizing contacts 
along the DNA binding helix. In order to test these possibilities, we 
constructed several POUhd point mutants and tested their ability to 
interact with full-length Ets-1 in GST-pulldown assays. As shown in 
figure 3A, Pit-1-A3, in which the three principal phosphorylation sites 
(S115, T219, T220) are mutated to alanines, showed a 1.4 fold 
increase in Ets-1 binding. In order to test the effect of a 
phosphorylated T220, we substituted it with an aspartic acid residue, 
which mimics a phosphorylated POUhd. Indeed, binding affinity of 
the T220D mutation was reduced by about one-third (Fig. 3B, lane 4). 
Thus, it appears that T220 represents one contact point for Ets-1 in the 
POUhd and that the phosphorylation status of T220 is an important 
regulator of the Ets-1/Pit-1 interaction. 
Residue E254 showed a significant (>15 Hz) change in 
chemical shift upon addition of Ets-1 (235-304). This change in 
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chemical shift might reflect the relative flexibility of this residue, 
which is located in the loop preceding the DNA binding helix. 
However, in a previous study, mutation of this residue to alanine 
resulted in an increased binding affinity for N-CoR [46]. As shown in 
figure 3B, this mutation also increased Ets-1 binding by about two-
fold. 
In the crystal structure, the hydrophobic pocket next the W261 
is partially covered by K226. Modifying this residue might alter the 
accessibility of the hydrophobic pocket. Indeed, both the K226A 
(which removes the positive side chain) and K226D (which switches 
the charge from positive to negative) mutations strongly increased Ets-
1 binding. These results suggest that both the presence and charge of 
K226 are important in regulating the binding of Ets-1. Since the 
hydrophobic pocket is formed by a number of structurally important 
residues, it is not possible to remove it without affecting the overall 
structure of the POUhd. However, mutating W261 to a phenylalanine 
should alter the pocket to some extent, without drastically affecting 
the folding of the POUhd. As shown in fig 3B, the binding affinity of 
W261F POUhd is increased fifteen- old. 
Moderate changes in chemical shift occurred along the C-
terminal part of the DNA binding helix. Tse may reflect stabilizing 
contacts with Ets-1 of the residues involved. However, mutations 
R268A and K270A hardly affected Ets-1 binding (Fig. 3B). Finally, 
we tested whether L288 at the C-terminus is involved in Ets-1 binding. 
Surprisingly, L288A POUhd s owed an increased binding affinity 
(Fig. 3B), which indicates that L288 may be in close proximity to a 
hydrophilic interaction domain. 
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Figure 3 
Effect of point mutations of Pit-1 homeodomain on binding of p68 c-
Ets-1. In vitro transcribed and translated [35S]-labeled proteins were 
bound to 20 mg of GST fusion proteins as described in materials and 
methods. Nonspecific binding to GST alone was subtracted from 
total binding and specific binding is expressed as % of input 
normalized for equal loading of fusion constructs. The graphs 
contain the mean ± SEM of data from 3 experiments. Asterisks 
represent a change that is statistically different from wild-type 
binding, p<0.05. 
A) Mutation of Pit-1 serine/threonine phosphorylation sites to alanine 
increases p68 Ets-1 (190-257) binding. 
B) Binding of [35S]-Ets-1 to GST and GST- Pit-1 (199-291) wild-type 
and mutants. 
 
3.5 Discussion 
There have been relatively few NMR studies on protein-
protein interactions to date [64,215,216]. The interaction partners in 
these studies all formed high affinity complexes. Here we report a 
NMR study on a 75 AA polypeptide spanning the Pit-1 POU 
homeodomain (AA 213-289) and a 70 AA region of the Ets-1 RIII 
activation domain (AA235-304), which we have shown to be the 
essential domains for the interaction between the two full-leng h 
proteins. The full-length proteins have been shown to interact in vivo 
with sufficient affinity to be detected by fluorescence resonance 
electron transfer (FRET) [217]. At conditions optimal for the NMR 
measurements, these two protein domains did not bind each other with 
high affinity the KD being in the micro to millimolar range. Even with 
this rather weak interaction, we were still able to show clear changes 
in chemical shift of the amino protons of the POUhd after addition of 
Ets-1 (235-304). 
In the case of the POU family member Oct-1, the DNA bound 
crystal structure and the solution structure are highly similar 
[135,218], since the Oct-1 and Pit-1 homeodomain are highly 
homologous, we presume that this will also be the case with the 
POUhd solution structure. We were in fact able to track all a-heli es, 
as they were resolved in the crystal structure by NH(i, i+1) contacts in 
the 3D-15N-NOESY HSQC. Therefore we can directly correlate the 
amount of chemical shift difference per amide proton to the known 
crystal structure of the POUhd [131], which is shown in figure 4A 
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(page 82). All amide protons that displayed more than 10 Hz change 
in chemical shift are located on one side of the protein, which would 
put the Ets-1 interaction region on the top side of the POUhd. One 
limitation of this approach is that changes in chemical shift for any 
given backbone amide are indirect evid nc  that its side chain is 
involved in the interaction. Therefore, we verified our results by 
interaction assays. 
Our results show large changes in chemical shift of the 
backbone amides around T219 and T220, which indicates that some 
part of Ets-1 (235-304) is in close proximity to these residues. 
Regulated phosphorylation of these threonines occurs i  vivo, either as 
targets of PKA or of a cell cycle-dep ndent kinase [142]. There have 
been conflicting reports on the influence of phosphorylation of 
threonine 220 with regard to DNA binding [141,142,219]. 
Furthermore, Pit-1-A3, in which the three principal phosphorylation 
sites (S115, T219, T220) are mutated to alanines, was unaffected or 
slightly less efficient than wild-type in activating transcription on the 
GH and PRL promoters in transient transfections [142,145]. Using Pit-
1-A3 in the HeLa reconstitution system, it was shown that removing 
the phosphorylation sites did not affect synergistic activation of the 
prolactin promoter with Ets-1 [125]. Because in transient over-
expression, subtle differences in binding affinity may be lost, we 
tested the ability of Pit-1-A3 to interact with Ets-1 in a GST-pulldown 
assay. We found that Ets-1 binding of Pit-1-A3 was about 1.4 fold 
increased, while introducing a negative charge at the position of T220 
reduces Ets-1 binding by about one-third. It is possible that this effect 
would be more pronounced with an actual phosphorylated threonine, 
which has a slightly different size and charge distribution than an 
aspartic acid. The reduction in binding affinity is not dramatic in our 
assay. However, given the bidentate nature of the interaction, the fact 
that this reduction is caused by a single point mutation seems all the 
more significant. Furthermore, the loss of about ne-third of binding 
affinity could very well influence subtle in vivo equilibria. Therefore, 
even though phosphorylation of T220 does not seem to serve as an 
on/off switch for Ets-1 binding, it might well be an important 
regulatory mechanism. 
Alternatively, the changes in chemical shift in the region 
around T219/220 might reflect secondary effects of binding of Ets-1 to 
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the hydrophobic pocket next to W261. The accessibility of this 
hydrophobic pocket seems to be modulated by the side chain of K226. 
In the crystal structure, Pit-1 is bound to DNA as a dimer. In one of 
the homeodomain structures in the crystal, K226 made a contact to the 
phosphate backbone of the DNA, folding over the hydrophobic 
pocket. However, in the other homeodomain in the protein dimer, th  
side chain of K226 is pointing away from the DNA, exposing the 
hydrophobic pocket (figure 4B). The presence of K226 is detrimental 
to the association of Ets-1, since truncating this side chain or 
switching its charge clearly increases Ets-1 binding. These findings 
present an interesting opportunity for an additional level of control for 
Pit-1/Ets-1 complex formation, as Pit-1 has been shown to be 
acetylated by CBP in vitro [79] and both Pit-1 and Ets-1 are able to 
bind CBP/p300 [46,220,221]. Based on our results, this acetylation 
could take place on K226 which would serve to increase association 
with Ets-1 by increasing accessibility of the hydrophobic pocket, thus 
decreasing the off-rate of Ets-1. Increased stability of the Pit-1/Ets-1 
complex could in turn enhance synergistic activation of the prolactin 
promoter. Using our data, we can suggest a model for the association 
of Ets-1 with Pit-1 (Fig. 4C). Depending on the post-tran lational 
modification state of the POUhd, Ets-1 will dock in the hydrophobic 
pocket next to W261 and contact the region around T220. Additional 
stability will be provided by residues at the C-terminus of the DNA 
binding helix and by the region around L288. 
Several other transcription factors, such as N-CoR, vitamin D 
receptor, Oct-1, and GATA-2 interact with Pit-1 hrough te 
homeodomain [46,147,152,162]. Oct-1 and Pit-1 can dimerize via the 
POU domain. In the absence of a cocrystal structure of an Oct-1 / Pit-1 
heterodimer bound to DNA, we speculate that the regions involved in 
this interaction are the same as those that allow homo-dimerization of 
Pit-1. This would mean that the C-terminus of the POU-homeodomain 
would dock in a hydrophobic pocket located between a-h lic s 1 and 
4 on the POU-specific domain. The association with the vitamin D 
receptor has been analyzed by deletion analysis, in which the N-
terminal half of the homeodomain proved vital for the interaction, 
while the C-terminal half accounted for half the binding affinity. 
These data do not exclude a similar binding interface as the one we 
have proposed in this study. The interaction of Pit-1 with N-CoR is 
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not yet very well characterized. The fact that a point mutation in the 
POUhd increased the affinity of Pit-1 for N-CoR implies that the 
POUhd is involved in this interaction [46]. Since that same mutation 
(E254A) also increased the affinity for Ets-1, it is tempting to 
speculate that these proteins might compete for the same binding 
interface. The interaction with GATA-2 will be discussed in more 
detail below. Apart from the hig  sensitivity, one of the advantages of 
our NMR approach over random mutagenesis or deletion experiments 
is that in one experiment, the entire protein can be probed for 
interaction. This means that combinations of residues or structural 
motifs that may not be affected with a single point mutant can be 
identified. Even if the proteins of interest bind one another with 
moderate affinity, this approach can still produce valuable information 
on protein-protein interactions. 
 
3.6 Addendum: HSQC-monitored titrations of the Pit-1 
POUhd with GATA-2. 
 
3.6.1 Introduction 
Like Ets-1, GATA-2 also interacts with the Pit-1 POUhd (see 
chapter I). Some of the essential residues on the POUhd for binding 
GATA-2 have been identified by mutagenesis coupled with interaction 
assays [162]. These residues include R215 and K216 at the N-
terminus and P239 and Q242 at the beginning of the second helix of 
the POUhd. None of the amide protons of these residues showed any 
significant change in chemical shift upon addition of Ets-1 (235-304), 
which indicates that GATA-2 probably employs a binding interface 
that is different from Ets-1. However, it is not excluded that part of the 
contacts may coincide with those of Ets-1. Fur hermore, as mentioned 
above, patches of amino acids that are involved in an interaction may 
be missed in a screening using single point mutants.  
Here we perform a similar HSQC-monitored titration as 
described above, using a purified peptide containing both GATA-2 
zinc fingers, which should bind the POUhd based on data from Dasen 
et al. [162]. The resulting changes in the POUhd spectrum indicate 
that GATA-2 likely utilizes a different interaction interface on the 
POUhd than Ets-1. 
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3.6.2 Materials and Methods: Proteins and NMR 
 15N-Pit-1 POUhd (213-289) was expressed and purified as 
described above. The human GATA-2 (290-409) peptide containing 
both the N- and C-terminal zinc fingers was a kind gift from Dr. David 
Gordon (University of Colorado Health Sciences Center, Denver). 10 
mg of lyophilized peptide was dissolved in 5 ml 0.05 % trifluoroacetic 
acid with 1.1 equivalent of ZnCl2, after which the pH was slowly 
increased to pH 6.0 by small additions of 0.1 M of NaOH. The 
GATA-2 peptide was concentrated in an Amicon stirred ultrafiltration 
cell (Millipore) using a 3 kD cut-off filter. The buffer of both the 15N-
POUhd and GATA-2 (290-409) was exchanged to a final 30 mM 
CD3COOH (pH 6.0), 100 mM NaCl and 1 mM dithiotreitol (DTT). 
NMR experiments were carried out at described above. 
 
3.6.3 Results / Discussion 
 During the reconstitution with zinc, a substantial amount of 
GATA-2 peptide was lost due to precipitation (final solution was 0.2 
mM in 0.5 ml). Therefore, using a 0.5 mM 15N-POUhd we were able 
to add GATA-2 only to a final 0.4 molar equivalent. Nevertheless, the 
HSQC spectrum of the POUhd did show changes that were dependent 
on the concentration of the GATA-2 peptide. Because of the low 
amount of GATA-2 added, the amount of chemical shift difference is 
smaller than with the Ets-1 titration. Figure 5 shows the level of 
chemical shift difference plotted against the primary structure of the 
POUhd. 
The overall pattern differs from the one seen with the Ets-1 
titration (Fig. 2B). The region that is most affected by the presence of 
GATA-2 is located at the N-terminus of the POUhd, which is in good 
agreement with previous results [162], where R215 and K216 were 
shown to be vital determinants for GATA-2 binding. Apart from the 
N-terminal region, only the amide protons of L253 and L288 were 
affected above background level. This change in chemical shift may 
reflect local flexibility of the loop between helices 2 and 3. On the 
other hand, L253 is located within 10Å of T220 in the tertiary 
structure. T220 is the last residue that is significantly (>10 Hz) 
affected in the N-terminal region. Thus L253 may be part of the same 
interaction domain that includes R215 and K216. The significance of 
the change in chemical shift for L288 cannot be determined at present. 
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The same residue did affect Ets-1 binding, which may indicate that the 
two factors share an interaction domain at the C-terminus. 
Alternatively, L288 might be more susceptible to changes for its 
location at the extreme C-terminus of the POUhd. 
 
 
 
 
Figure 5 
HSQC Monitored titration of the 15N-POUhd with the Zn-finger region 
of GATA-2. 
A) Selected region showing superimposed spectra of free POUhd 
(black) and after the addition of 0.4 molar equivalent of GATA-2 
(290-409) (white). 
B) Combined 1H-15N chemical shift perturbations caused by the 
addition of 0.4 molar equivalent of GATA-2 (290-409) mapped 
against the secondary structure of the POUhd. The values are 
calculated as Euclidian distances between peaks: 
DdNH=((Dd15N)2 + (Dd1H)2)1/2, where Dd15N and Dd1H denote the 
nitrogen and proton shifts in Hz, respectively. 
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Dasen et al. identified two more POUhd mutations that 
affected GATA-2 binding: P239S and Q242A. Of these two residues 
P239 cannot be studies by our approach, since it has no amide proton. 
The amide proton of Q242 and the surrounding residues were 
unaffected in our study, indicating that there are no major contact 
points in that region of the POUhd. This apparent contradiction could 
be explained by a loss of helix capping with the Q242A mutation, 
which could disrupt the formation of the second a-h lix of the 
POUhd. Resulting changes in the overall structure of the POUhd 
might affect GATA-2 binding. An alternative explanation is the use of 
a GATA-2 peptide in this study instead of the full-length protein by 
Dasen et al. 
In conclusion, the interacion with GATA-2 seems to involve 
an interaction domain at the N-terminus of the POUhd. Even though 
the interaction with Ets-1 also involved residues in the N-terminus of 
the POUhd, the overall pattern of chemical shift changes appears to be 
quite different. Therefore, it is likely that GATA-2 uses a different 
interaction interface than Ets-1. Further NMR experiments coupled 
with mutational analysis are required to further define this interface.
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Figure 4 
Mapping of chemical shift perturbations to the POUhd structure. 
Surface density representations of the crystal structure of the 
POUhd bound to DNA. These fragments were taken from the crystal 
structure as resolved by Jacobson et al (1997). 
A) The results from figure 2B indicated by color- ding. Chemical 
shift changes > 25 Hz are colored dark red, changes between 25 
and 15 Hz red and between 15 and 10 pink. Unaffected residues are 
colored yellow. 
B) Two orientations of K226 (blue) in the Pit-1 d mer with different 
accessibility of the hydrophobic pocket formed by V257, V258, I222 
and W261 (colored in beige). The DNA has been deleted for clarity. 
C. Model for association of Ets-1 to the POUhd. K226 is shown in 
blue, the hydrophobic pocket in beige and T220 in green. Since the 
crystal structure does not extend beyond residue K273, an extended 
tail was added to represent the C-terminus of the POUhd. Ets-1 
could, depending on the post-translational state of the POUhd, dock 
in the hydrophobic pocket next to W261. Additional stabilizing 
contacts may be made at the C-terminus of the DNA recognition 
helix (helix 3) and at the region around L288. These pictures were 
generated using MSI’s Weblab viewer, Lite version (www.msi.com). 
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4.1 Abstract 
 
 The POU-domain transcription factor Pit-1 and Ets-1, a 
member of the ETS family of transcription factors, can associate 
in solution and synergistically activate the prolactin (PRL) 
promoter by binding to a composite response element in the PRL 
promoter. We have previously mapped the minimal interaction 
domains for the physical interaction to the Pit-1 POU-
homeodomain (POUhd) and a part of the activation domain of 
Ets-1. Furthermore, we have shown that the interaction domain 
for Ets-1 on the POUhd partially overlaps with its DNA binding 
interface. In this report we used mobility shift assays and HSQC-
monitored protein-DNA titrations to investigate the effect of the 
presence of the minimal Ets-1 interaction domain on DNA binding 
by the POUhd. Our results show that the minimal interaction 
domain of Ets-1 and the POUhd do not form a ternary complex 
with DNA and that this Ets-1 domain does not affect DNA binding 
by the POUhd. 
 
4.2 Introduction 
 
 The POU-domain transcription factor Pit-1 provides an 
excellent model system to study protein-protein and protein-DNA 
interactions. As one of the key regulators of gene expression in the 
anterior pituitary gland, Pit-1 is required for the expression of the 
growth hormone (GH), prolactin (PRL) and thyrotropin (TSHb) genes 
[184,208]. However, in order to selectively stimulate these promoters, 
Pit-1 needs to interact with a number of other transcription factors 
[92]. One of these factors is ETS-family member Ets-1 [167], which 
interacts with Pit-1 in solution and binds to a composite Ets-1 / Pit-1 
response element in the FP-4 region of the PRL promoter [108].
Together they synergistically activate transcription of the PRL 
promoter. We have previously investigated the interaction of the 
minimal interaction domains of both proteins, which comprise the 
POU-homeodomain (POUhd) of Pit-1 and a part of the region III 
activation domain of Ets-1 [125] (chapter III). However, the exact 
contribution of the physical interaction to the cooperative function on 
PRL gene activation of both proteins is as yet unclear. Thus far, efforts 
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to show a ternary complex with the full-length proteins and the 
composite DNA binding element have been unsuccessful. Therefore, 
we extended our studies of the minimal Pit-1 and Ets-1 interaction 
domain to include DNA. The minimal interaction domain of Ets-1 
does not contain the ETS-DNA binding domain, but might be 
recruited to the DNA by the POUhd. Since the interaction domain of 
Ets-1 on the POUhd overlaps to some extent with the DNA binding 
interface, it is possible that the presence of Ets-1 might modulate the 
DNA binding affinity or specificity of the POUhd. Here we report 
HSQC-monitored protein-DNA titrations of 15N-labelled Pit-1 POUhd 
(residues 213-289) with the Pit-1 site of the FP-4 region of the PRL 
promoter. In addition, we perform the same titration on a preformed 
Ets-1 (235-304) / POUhd complex. The NMR data, coupled with 
biochemical analysis, indicate that the minimal interaction domains f 
Ets-1 and Pit-1 are unable to bind simultaneously to DNA and that the 
DNA binding affinity of the POUhd is unaffected by the presence of 
the minimal interaction domains of Ets-1. 
 
4.3 Materials and Methods 
 
4.3.1 Proteins and DNA 
Protein expression and purification was done as described in 
chapter III. The PRL-4P oligonucleotide 5'-GCC TTT GGC CTA ATT 
AAT CAA AAG GG-3' and its opposite strand 5'-CCC TTT TGA TTA ATT 
AGG CCA AAG GC-3' containing the Pit-1 binding sequence (-209 to -
190) from the human PRL FP-4 region, with three CG base pairs at 
both the 5' and 3' ends to facilitate hybridization, were purchased from 
Roche. Lyophilized oligo was dissolved in H2O, denatured at 95°C for 
5 min and hybridized by cooling to room temperature. After 
hybridization, the oligo was loaded on a fast-flow Q-sepharose column 
equilibrated in 50 mM NaxHyPO4 (pH 6.0), 100 mM NaCl and 1 mM 
dithiotreitol (DTT). After washing, the DNA was eluted in a linear 
gradient from 100-2000 mM NaCl. Peak fractions were pooled and 
concentrated to approximately 1.8 mM with an Amicon stirred 
ultrafiltration cell (Millipore) using a 1 kD cut-off filter. The buffer 
was exchanged to a final 50 mM NaxHyPO4 (pH 5.5), 100 mM NaCl 
and 1 mM dithiotreitol (DTT). For the gel mobility shift assay, the
oligo 5'-GGA GCT CGA GCT CTC ATT TCC TTT TGG CCT AAT TAA TCA 
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AAA TCC TTC CCT CGA GGA GG-3' and its opposite strand 5'-CCT CCT 
CGA GGG AAG GAT TTT GAT TAA TTA GGC CAA AAG GAA ATG AGA 
GCT CGA GCT CC-3' (Pharmacia) containing the -221 to -183 region 
from the hPRL promoter (flanked on both sides by an XhoI site) were 
end labeled using T4 kinase (Pharmacia), denatured at 95°C for 5 min 
and hybridized by cooling to room temperature. After hybridization, 
the oligo was purified by polyacrylamide gel electrophoresis. 
 
4.3.2 NMR Spectroscopy 
NMR experiments were carried out at 305 K (32°C) on a 
Bruker Avance 750 spectrometer. The protein concentration was 1 
mM in all experiments, 10% D2O was added to obtain a lock signal. 
Spectra were processed using the softwarpackage NMRPipe [212] 
and analyzed using NMRVIEW [213]. Protein-DNA titrations were 
carried out by repeated addition of small volumes of the PRL-4P oligo 
to a 15N-labelled Pit-1 homeodomain sample and recording a 750 MHz 
1H15N-HSQC spectrum after each addition. The sample was 
concentrated in an Amicon stirred ultrafiltration cell to keep the total 
volume around 500 ml. 
 
4.3.3 Gel mobility shift ass y 
Pit-1 POUhd (213-289) and Ets-1 (235-304) were purified as 
described in chapter III. Protein dilutions were made in 50 mM Tris-
HCl (pH 7.5), 1 mM EDTA (pH 8.0), 100 mM NaCl, 10% glycerol 
and 10 mM b-mercaptoethanol. After 15 min. preincubation at room 
temperature, POUhd and Ets-1 (235-304) proteins were added to 
approximately 2 fmol DNA in a final reaction mixture of 20 ml 
containing 20 mM HEPES-KOH (pH 7.5), 100 mM NaCl, 1 mM 
EDTA (pH 8.0), 1mM DTT, 0.025% NP-40 and 1 mg poly dIdC 
competitor DNA. After another 15 min. at room temperature, 2 ml of 
0.02% xylene cyanol was added and the samples were run on a 8% 
polyacrylamide gel containing 0.01% NP-40, at 4°C for 3 h at 30 mA. 
The gel was dried and the DNA was visualized by autoradiography. 
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4.4 Results 
 
4.4.1 Ets-1 (235-304) does not form a ternary complex with the 
POUhd in EMSA. 
 Physical interaction of Ets-1 and Pit-1 involves a part of the 
RIII activation domain of Ets-1. As shown in chapter III the 
interaction interface for Ets-1 on the POUhd of Pit-1 overlaps to some 
extent with the DNA binding surface of the POUhd. This raised the 
question whether both the minimal domain interaction partners could 
simultaneously bind DNA. We addressed this question by testing 
whether addition of the Ets-1 interaction domain, which does not bind 
DNA by itself (data not shown), could supershift a POUhd / DNA 
complex in a bandshift (EMSA) assay. At the conditions used in the 
EMSA, the POUhd and Ets-1 are able to bind each other (unpublished 
data). As shown in figure 1A, the Pit-1 POUhd can bind to a probe 
containing the FP-4 region of the human PRL promoter. At higher 
concentration, a slower migrating complex appeared, which likely 
reflects the POUhd bound as a dimer. To examine whether a ternary 
Ets-1 / POUhd / DNA complex could be formed, an amount of POUhd 
that would shift about 50% of the labeled probe was incubated with 
increasing amounts of Ets-1 (235-304) prior to the addition of the 
DNA probe. As shown in figure 1B, Ets-1 (235-304) was unable to 
form a ternary complex with the DNA bound POUhd. In fact, even 
addition of an excess of Ets-1 (235-304) did not affect the POUhd / 
DNA complex in any way, which indicates that the POUhd has a 
much higher affinity for DNA, than for Ets-1 (235-304). Furthermore, 
we conclude that the amino acids on the POUhd that are not involved 
in DNA binding, but are contacted by Ets-1 (235-304) are insufficient 
to retain Ets-1 in this assay. 
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Figure 1 
A) DNA binding of an increasing amount of the Pit-1 POUhd to an 
oligo containing the footprint 4 region from the human PRL promoter. 
The POUhd initially binds as a monomer, but will dimerize at higher 
concentration. 
B) DNA binding of a constant amount of the POUhd, with the 
addition of an increasing amount of Ets-1 (235-304). Ets-1 (235-304) 
is unable to form a ternary complex with DNA-bound POUhd; neither 
does the presence of Ets-1 (235-304) decrease DNA binding by the 
POUhd. 
 
 
4.4.2 HSQC-monitored DNA titrations of the Pit-1 POUhd. 
 Since EMSA analysis is not a sensitive method to pick up 
weak interactions, we used HSQC-monitored titration of 15N-labeled 
POUhd with unlabeled DNA to verify if a ternary complex could exist 
in solution. In order to do this, we first needed to investigate the 
effects of a titration of the 15N-POUhd with an oligonucleotide 
containing the Pit-1 binding site of the FP-4 region from the PRL 
promoter. Addition of small volumes of the 1.8 mM solution of the 
PRL-4P oligo resulted in slight precipitation, which cleared after 5 
minutes incubation at room temperature. 1H-15N HSQC spectra of the 
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15N-POUhd recorded after the each addition of DNA showed a gradual 
broadening of most signals i  the spectrum, indicative of a large 
molecular weight complex being formed. Figure 2A shows an overlay 
of a selected region of the free POUhd (black) spectrum and the same 
region after the addition of 1/6 molar equivalent of DNA to POUhd 
(gray). This region clearly shows that some signals (such as T220 and 
R268) are severely broadened and shifted, while others (such as V257, 
V258 and Q267) are moderately or hardly (E235) affected. 
Upon reaching equimolar levels of DNA, the spectrum had 
deteriorated to a point where many of the signals could not reliably be 
determined. The differences in chemical shift per residue after the 
addition of 1/6 and 1/3 molar equivalent of DNA compared to the free 
form are shown in figure 2B. All residues showed a proportional shift 
to the amount of DNA added. Even though almost all backbone 
amides were affected to some extent, the major changes in the spectra 
were, as could be expected, limited to the DNA binding helix (a-3) of 
the POUhd. Several signals such as N264, Q267 and R268 were 
already severely broadened upon the lowest addition of PRL-4P, 
which probably indicates intermediate exchange for these residues. 
These residues are in direct contact with the DNA in the crystal 
structure. The same line broadening can be seen with the backbone 
amide signals from T220, I221 and S222. These residues are located 
in the N-terminal flexible linker, which docks into the minor groove in 
the crystal structure. 
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Figure 2 
A) Overlay of a selected region of the 1H15N-HSQC spectrum of the 
15N-POUhd showing the free POUhd (black) and the spectrum after 
the addition of 1/6 molar equivalent of PRL-4P oligo to the POUhd 
(gray). 
B) Graphs showing the combined 15N-1H chemical shift 
perturbations, after the addition of 1/6 and 1/3 molar equivalent of 
PRL-4P oligo, mapped against the secondary structure of the 
POUhd. The values are the mean of two independent experiments 
and were calculated as Euclidian distances between peaks: 
DdNH=((Dd15N)2 + (Dd1H)2)1/2, where Dd15N and Dd1H denote the 
nitrogen and proton shifts in Hz, respectively. Major changes are 
restricted to the flexible N-terminus and the DNA binding helix (a-3) 
of the POUhd. 
 
4.4.3 The presence of Ets-1 (235-304) does not prevent DNA binding 
by the POUhd. 
 In order to assess whether Ets-1 (235-304) could modulate the 
DNA binding capability of the POUhd, we performed the same 
titration as described above on a preformed Ets-1 (235-304) / POUhd 
complex. As described in chapter III, at the conditions used to record 
the spectra, it was not possible to add more than an equimolar amount 
of Ets-1 (235-304) to the POUhd without severe precipitation of Ets-1 
(235-304). Therefore, in order to obtain a saturated POUhd / Ets-1 
(235-304) complex, we added a 1.1 molar excess of Ets-1 (235-304) to 
a 15N-labeled POUhd sample. After 5 minutes incubation at 32°C, the 
precipitate was removed by centrifugation and a 1H15N-HSQC 
recorded. The resulting spectrum displayed the same shifts as 
described in chapter III (data not shown). Upon addition of the PRL-
4P oligo the same line broadening and peak shifts occurred as seen 
with the free POUhd / DNA titration (Figure 3). The overall spectrum 
after the addition of 1/3 molar equivalent of DNA was highly similar 
to the corresponding spectrum of the free POUhd / DNA titration. 
Furthermore, the residues that directly contact DNA in the crystal 
structure were severely broadened and shifted after the lowest 
additions of PRL-4P, as they were with the titration of the free 
POUhd. Thus, in agreement with the EMSA, the NMR data indicates 
that the POUhd binds with higher affinity to its target DNA sequence 
than to Ets-1 (235-304) and that the binding of Ets-1 (235-304) is 
prevented by the presence of DNA. 
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Figure 3 
A) Overlay of a selected region of the 1H15N-HSQC spectrum 
showing the 15N-POUhd / Ets (235-304) preformed complex without 
DNA (black) and after the addition of 1/3 molar equivalent of PRL-4P 
oligo (white). 
B) Overlay of a selected region f the 1H15N-HSQC spectrum 
showing the POUhd in the presence of 1/3 molar equivalent of PRL-
4P (black) and the POUhd / Ets (235- 04) preformed complex after 
the addition of 1/3 equivalent of PRL-4P oligo (white). 
 
4.5 Discussion 
 The crystal structure of Pit-1 bound as a dimer [131] provides 
a static picture of the POU domain bound to the DNA as a dimer. Here 
we report a NMR study of DNA binding by the POUhd, which allows 
for a more dynamic approach. Titration of 15N-POUhd with the PRL-
4P showed a rapid line broadening of the HSQC spectrum, which 
indicates the formation of a large complex in solution. Specific 
changes in chemical shift and severe line broadening occurred on the 
residues that directly contact DNA in the crystal structure. For 
example, the amide proton from residue N264 was no longer 
detectable after the lowest addition of PRL-4P. 
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Figure 4 
Three views of the cocrystal structure as determined by Jacobson et 
al. Color-coding indicates residues that are affected in our NMR 
study by the minimal Ets-1 interaction domain (red), DNA (green) or 
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both (blue). It is clear that the interaction domains overlap to a large 
extent, while the "back" of the protein is not affected by either Ets-1 
or DNA. 
 
 
Overall, the amount of chemical shift difference was 
remarkably proportional to the amount of PRL-4P added, which 
indicates that there are no sudden structural transitions in DNA 
binding by the POUhd. However, the residues R271, V272 and K273 
at the end of the DNA binding helix (a-3) show a significant 
difference in chemical shift in the DNA titration. These residues do 
not contact DNA in the crystal structure, but instead form the 
dimidiation interface for the POU-specific domain of the other 
monomer. Dimer formation causes a slight unraveling of the C-
terminus of the DNA binding helix. Given the relative concentration 
of POUhd and DNA in our NMR study and the EMSA analysis, it is 
likely that the POUhd will dimerize on the DNA. However, we 
presume that in the absence of a POU-specific domain, a bound 
POUhd monomer will not make protein-protein contacts with the 
other monomer. Thus, in the absence of a POU-specific domain to 
interface with, the residues from the dimidiation interface may extend 
the DNA binding helix upon the addition of DNA, which could 
explain the changes in chemical shift. 
 Almost identical results were obtained with the DNA titration 
of a preformed POUhd / Ets-1 (235-304) complex. The resonances 
from the preformed complex rapidly shifted to the DNA-bound form 
with the addition of PRL-4P. Small differences between the POUhd / 
DNA and the POUhd / Ets-1 / DNA spectra can be explained by the 
presence of a small population of POUhd / Ets-1 complex in the latter 
spectrum. The absence of any major difference between these 
titrations is in agreement with the EMSA data and confirms that the 
relative affinity of the POUhd for DNA is much higher than for Ets-1 
(235-304). 
Figure 4 shows the crystal structure of the POUhd, with the 
residues that are involved in DNA binding and Ets-1 binding color-
coded. It is clear from this figure that there is significant overlap 
between the interaction interfaces for DNA binding and Ets-1 
interaction. Our data indicates that amino acids on the POUhd that are 
not involved in DNA binding, but are contacted by Ets-1 (235-304) 
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(like for instance L288, which is not show in the crystal structure) are 
insufficient to retain Ets-1 in this assay. 
Since the Ets-1 peptide used in this study does not contain the 
ETS DNA-binding domain, our study does not preclude ternary 
complex formation with the full-l ngth proteins. Such a ternary 
complex would not necessarily use the same contacts as seen with the 
interaction of the minimal interacting domains. It is unknown at 
present whether the full-length proteins affect each other's DNA 
binding affinities. This is the case with the interactions between Pit-1 
and GATA-2 [162], where binding of Pit-1 nhibits DNA binding by 
GATA-2, unless the GATA-2 recognition site has a neighboring Pit-1 
binding site. DNA binding by Ets-1 can be modulated by interaction 
with other factors like Pax-5 [222] and AML1/CBFa2 [172,173]. The 
latter interaction relieves auto-inhibition of Ets-1 DNA binding by 
binding the auto-inhibitory region in exon VII (238-3 8) of Ets-1. 
Since this region partially overlaps with the interaction dom in for Pit-
1 (190-257), it is possible that Pit-1 exerts a similar effect as 
AML1/CBFa2, relieving auto-inhibition of Ets-1 DNA-binding. 
Future study could address these issues by EMSA analysis using the 
full-length Pit-1 and Ets-1 proteins and structure determination of the 
full-length proteins bound to the PRL-4P composite element by 
crystallography. 
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5.1 Abstract 
 
 The POU-domain transcription factor Pit-1 s involved in 
the selective expression of the GH, PRL and TSH-b genes in the 
anterior pituitary. In order to modulate its transactivation 
properties, Pit-1 interacts with a number of other transcription 
factors. Here we report a novel interaction of the transcription 
activation domain of Pit-1 with the 13S splice variant of the 
adenoviral immediate early gene product E1A. This interaction 
was dependent on the structure of the zinc-finger domain of 
conserved region 3. Co-transfection of E1A 13S, but not E1A 12S, 
with Pit-1 led to a decrease in Pit-1 mediated activation of both the 
GH- and PRL-promoters, indicating that a functional interaction 
may occur in vivo. 
 
5.2 Introduction 
In order to regulate activation of its target promoters, Pit-1 
functionally interacts with a number of other transcription regulators. 
As described in thegeneral introduction, a number of factors also 
physically associate with Pit-1 to regulate its function. This physical 
interaction is used to recruit key transcriptional regulators such as 
CBP and N-CoR to a Pit-1 responsive promoter. The adenovirus 
immediate early gene product E1A is a transcription cofactor that is 
expressed upon infection of a host cell ([223] reviewed in [224]). Like 
Pit-1, E1A can also interact with CBP/p300 [76]. Additional 
interactions include a large number of key transcriptional regulators 
such as the SWI/SNF [225] and Mediator complexes [41]. 
Furthermore, E1A can interfere with the host cell cycle by interacting 
with cellular factors such as the retinoblastoma protein (RB) [226]. 
Through these interactions E1A is able to prepare the cell for viral 
replication. Two different splice variants of E1A are known (Fig. 1), 
which differ in the insertion of the 48-amino acid Conserved Region-3 
(CR-3) domain. CR-3 contains a zinc-finger based activation domain, 
which can activate transcription by contacting important factors such 
as TBP [227,228], CBP [76,229], nuclear receptors [230,231] and 
several TAFs [232,233]. 
Here we report an in vitro interaction of the CR-3 activation 
domain with the activation domain of Pit-1. Furthermore, we show 
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that in contrast to E1A 12S, the presence of E1A 13S represses Pit-1 
mediated activation of the GH and PRL promoters in transient 
transfections. This repression is shown to be at least in part dependent 
on the structure of the CR-3 domain of E1A 13S. 
 
 
 
 
 
Figure 1 
Two splice variants of E1A differ in the insertion of the CR-3 domain 
(highlighted). The CR-3 domain contains a zinc finger and two 
hydrophobic patches (shown in bold). The location of the C174S 
mutation used in this study is indicated. 
 
 
5.3 Materials and Methods 
 
5.3.1 Plasmids 
The expression plasmids for the GST-fusions of the SP1 (140-
250), VP16 (411-490), Oct-1 (175-269), Retinoic acid receptor AF1 
(1-76) and the E1A CR-3 (142-188) activation domains were kindly 
provided by Dr. G. Folkers. For the transient transfections we used the 
previously described cytomegalovirus (CMV) promoter driven Pit-1
construct, GH and PRL-luciferase reporter constructs, Rous sarcoma 
virus (RSV) driven b-galactosidase and empty CMV-vector [234]. 
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RSV driven E1A 12S, 13S and C174S E1A 13S were also kindly 
provided by Dr. G. Folkers. All plasmids were transformed in E.coli 
DH5a and grown overnight at 37°C in LB medium containing 50 
mg/ml of ampicillin. Cells were harvested and plasmid DNA was 
extracted using a Jetstar maxiprep kit (Genomed). Concentration and 
purity of all DNA was determined by measuring absorption at 260/280 
nm. 
 
5.3.2 GST-pulldowns 
Glutathione agarose beads equilibrated with binding buffer (50 
mM TRIS pH 8.0, 100-2 00 mM KCl, 20% glycerol, 1 mM DTT, 1 
mM EDTA, 0.01% Triton-X100) were loaded with 0.5 ml of crude 
lysate (in 50 mM TRIS pH 8.0, 500 mM KCl, 10% glycerol, 1 mM 
DTT, 1 mM EDTA, 0.01% Triton-X100) from GST-fusion expressing 
E.coli BL21 by rotating for 1.5 hour at 4°C. After three washing steps 
with binding buffer, the beads were incubated with the target protein 
in 500 ml end volume for 1 hour at 4°C. After three more washing 
steps, bound proteins were boiled off the beads in sample buffer and 
detected by SDS-PAGE. 
 
5.3.3 Cell culture and transient transfections 
The human osteogenic sarcoma cells U-2 OS were grown in 
Dulbecco’s modified Eagle medium (DMEM, Life Technologies, 
Enc), supplemented with 10% fetal calf serum, 3.5 mmol L-glutamine, 
100 u penicillin and 100 mg/ml streptomycin. For transfection 9· 106 
cells were plated in six well plates at day 0. At day 1 (approximately 
25% confluency) cells were transfected by calcium-phosphate co-
precipitation. Each well was transfected with 3 mg reporter plasmid 
and 500 ng RSV-LacZ to normalize for transfection efficiency. The 
total amount of DNA was complemented to 4.375 mg by the addition 
of empty CMV vector. DNA was added to 125 ml 2X HBS pH 7.05 
(40 mM HEPES, 274 mM NaCl, 10 mM KCl, 1.4 mM 
Na2HPO4· 2H2O). Under vortexing 125 ml 0.25 M CaCl2 was added to 
obtain a fine precipitate. This precipitate was added to the cells, 17 
hours after which the medium was refreshed. Cells were harvested at 
31 hours after this. The cells were washed with PBS and 300 ml of 
lysisbuffer (25 mM TRIS-PO4, 15% glycerol, 1% Triton-X100) was 
added per well. After 10 min incubation on ice, the cells were scraped 
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from the wells and lysates were collected in eppendorf tubes. After 
centrifugation (3 min, 4°C, 14,000 rpm), the supernatant was stored at 
-80°C until luciferase and b-galactosidase assays were performed. 
Luciferase and b-galactosidase assays were done as described 
previously [234]. Luciferase values were divided by the b-
galactosidase activity to correct for transfection activity. All 
transfections were performed in duplicate in at least two separate 
experiments. 
 
5.4 Results 
 
5.4.1 The Pit-1 TAD, but not the POU-domain, associates with the 
E1A-13S CR-3 Zn-finger.  
 Most proteins that physically associate with Pit-1 do so by 
contacting the POU DNA binding domain. In order to identify factors 
that would interact with the Pit-1 TAD, we screened a number of 
GST-immobilized factors for their ability to pull down purified Pit-1 
TAD (residues 48-129) at different salt concentrations. During this 
screening, we found that the CR-3 domain of the immediate early gene 
product of adenovirus (E1A) interacted with the Pit-1 TAD at high salt 
concentration (Fig. 2a). Titration of the salt concentration showed that 
the interaction remained stable up to 2 M of KCl, although the optimal 
concentration was around 500 mM. From this we conclude that the 
interaction likely includes a number of hydrophobic contacts. Addition 
of 10 mM EDTA completely blocked the interaction (Fig. 2b). 
Removal of the coordinated zinc ion from the zinc finger by EDTA is 
likely to disrupt the overall fold of the CR-3 domain. Therefore, the 
structure of the CR-3 zinc finger is an important determinant for 
binding of the Pit-1 TAD. In contrast, GST-immobilized E1A CR-3 
was unable to pull down any significant amount of the Pit-1 POU-
domain at any of the salt concentrations tested (Fig. 2c). 
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Figure 2 
A) Coomassie stained gel of the screening of different activation 
domains for binding to the Pit-1 TAD at 1 M KCl. Molecular size 
marker and 5% input lanes are indicated. Not bound (NB) lanes 
show samples taken after the incubation of the fusion proteins with 
the Pit-1 TAD, before the first wash. Pellet (P) lanes show all bound 
proteins after the final wash step. Except GST-E1A CR-3, none of 
the fusions retained any Pit-1 TAD at these conditions. 
B) Interaction of E1A CR-3 domain with the Pit-1 TAD required at 
least 500 mM KCl and remained stable up to 2 M of KCl. The 
addition of 10 mM EDTA completely blocked association at 1500 
mM of KCl. 
C) The POU domain of Pit-1 was not retained by GST-E1A CR-3. 
Lane 1 shows 10% of the input Pit-1 POU-domain, lane 2 shows 
background binding to GST loaded beads. Binding of the POU-
domain by GST-E1A CR-3 at 150 mM KCl was minimal both in the 
absence (lane 3) and presence (lane 4) of 10 mM EDTA. Lanes 5 
and 6 show background binding to GST loaded beads and binding of 
the POU-domain by GST-E1A CR-3 at 1000 mM KCl. 
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5.4.2 E1A 13S represses transcription activation by Pit-1 on GH and 
PRL promoters. 
 Since the interaction between the Pit-1 TAD and the E1A 13S 
CR-3 region had not been reported previously, it was not known 
whether association of E1A 13S would in any way affect Pit-1 
function in vivo. In order to investigate this issue, we tested the 
influence of E1A 13S on Pit-1 activation of the GH and PRL 
promoters in co-transfection assays in U-2 OS cells, which do not 
express endogenous Pit-1. As shown in figure 3, Pit-1 is capable of 
stimulating both the GH and PRL promoters. The amount of Pit-1 
expression vector (375 ng) transfected, resulted in an about 4-fold 
stimulation of the GH promoter. Pit-1 was much more efficient in 
stimulating the PRL promoter, as the same amount of expression 
vector resulted in a 145-fold activation. This difference in Pit-1 
response likely reflects different coactivator requirements of each 
promoter. Adenovirus E1A 13S did not affect basal transcription 
levels of the GH and PRL promoters at any of the amounts 
transfected. However, in co-transfection with Pit-1 ncreasing amounts 
of E1A 13S resulted in a concentration dependent repression of Pit-1 
promoter activation. O  the GH promoter E1A 13S was able to repress 
Pit-1 activation to basal level when 500 ng of expression vector was 
co-transfected. The effect on the PRL promoter is less dramatic with a 
1.4 fold repression at 500 ng of E1A 13S, again indicating the 
difference between the GH and PRL promoters. 
 
5.4.3 CR-3 zinc finger is partially involved in E1A 13S mediated 
repression of Pit-1 activity. 
 In order to test whether the CR-3 domain is the part of E1A 
13S that mediates the repression of Pit-1 activation, we performed co-
transfection assays with E1A 12S. The 12S splice variant of E1A lacks 
the CR-3 domain and should therefore be affected in its ability to 
influence Pit-1 mediated activation. Beyond a slight repression of the 
basal transcription level, E1A 12S hardly affected the GH promoter. In 
contrast to the repression of Pit-1 activation by E1A 13S on both the 
PRL and GH promoters, co-transfection of the 12S variant with Pit-1 
resulted in a markedly higher (about 1.7 fold at 125 ng of co-
transfected E1A 12S) activ tion of the GH promoter. This activation 
was lost at higher amounts of co-transfected E1A 12S, probably due to 
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quenching effects. At 500 ng of co-transfected DNA, E1A 12S did not 
affect Pit-1 activation, while the same amount of E1A 13S repressed 
Pit-1 activation almost to background level (compare fig. 3 and fig. 4). 
Therefore, the repression of Pit-1 mediated GH activation by E1A 13S 
requires the presence of the CR-3 domain. 
 
 
 
 
Figure 3 
Effects of transfection of E1A 13S and co-transfection with Pit-1 on 
both GH and PRL promoters. Activation by 375 ng of transfected Pit-
1 expression plasmid was normalized at 100%. The - lan shows 
basal activity of each promoter relative to Pit-1 stimulation. Amounts 
of E1A 13S are given in ng. 
 
 
 
 
Figure 4 
Effects of transfection of E1A 12S or C174S E1A 13S and co-
transfection of Pit-1 on the GH promoter. Activation by 375 ng of 
transfected Pit-1 expression plasmid was normalized at 100%. The - 
lane shows basal activity of each promoter relative to Pit-1 
stimulation. Amounts of E1A 12S and C174S E1A 13S are given in 
ng. 
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 Our in vitro data suggest that the structure of the zinc finger in 
the CR-3 domain is an essential determinant for binding the Pit-1 
TAD. Therefore we tested whether the C174S mutant E1A 13S could 
still repress Pit-1 activation. Mutating the C-terminal coordinating 
cysteine to a serine residue should disrupt the structure of the zinc 
finger. Once again, as shown in figure 4, C174S E1A 13S did not 
affect basal transcription levels of the GH promoter. Unexpectedly, 
the 13S mutant was still able to repress Pit-1 activa ion in a 
concentration dependent manner albeit with less efficiency than the 
wild type E1A 13S. 
 
5.5 Discussion 
 
 The adenovirus immediate early gene product E1A is a 
multifunctional protein that can interact with a wide variety of other 
proteins. Depending on the promoter context and cell type, E1A can 
both activate and repress transcription [235-237]. Here we report an 
interaction of the CR-3 of E1A with the activation d main of Pit-1. Of 
the many physical interactions that have been reported with Pit-1 only 
three seem to involve the TAD. The Estrogen and Thyroid receptor 
target a Y6Y6Y motif and a serine/threonine rich region in the TAD 
respectively [116,117], while P-OTX / Ptx-1 interacts with the entire 
TAD [148]. These interactions with the TAD of Pit-1 all resulted in 
synergistic activation of the GH and PRL promoters. Here, co-
transfection of E1A 13S with Pit-1 resulted in a repression of Pit-1 
activation on both the GH and PRL promoters in U-2 OS cells. This 
repression was solely mediated by the presence of the CR-3 domain, 
as E1A 12S (which lacks the CR-3 domain) did not repress GH 
activation by Pit-1. In fact, for unknown reasons, co-transfection of 
low amounts of E1A 12S resulted in an increase in GH promoter 
activity. 
The PRL promoter was much more efficiently stimulated by 
Pit-1 than the GH promoter. This effect was also observed previously 
in HeLa and 293 cells (chapter II). Since the PRL promoter contains 
more Pit-1 binding sites than the GH promoter (Fig 4 in chapter I), this 
effect might simply be related to a more efficient Pit-1 b nding by the 
PRL promoter. Alternatively, the presence of a coactivator like Ets-1, 
which synergizes with Pit-1 on the PRL, but not on the GH promoter, 
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might explain the differential response of the GH and PRL promoters. 
Ets-1 likely is present in U-2 OS, as it is involved in hematopoietic 
development. In order to circumvent this problem of unknown 
cofactors, one could perform the same transfections in pituitary cell 
lines instead of U-2 OS cells, which do not normally express Pit-1. 
The presence of a coordinated zinc ion in the CR-3 zinc finger 
was required for the in vitro interaction with the Pit-1 TAD. However, 
the in vivo effect of E1A 13S was only partially dependent on the 
structural integrity of the zinc finger, as the C174S mutant was also 
capable of repression, albeit with less efficiency than the wild type. 
This might reflect an incomplete unfolding of the zinc finger structure 
by this mutation, compared to a complete unfolding when all zinc is 
chelated by EDTA. Alternatively, there might be other regions within 
the CR-3 domain that must cooperate with the zinc finger region to 
obtain full effectiveness. This is the case with the interaction of E1A 
13S with Drosophila TAFII110 / human TAFII135, where deletions in 
both the zinc finger and hydrophobic patches in the N- and C-t rminal 
part of the CR-3 domain (Fig. 1) showed diminished affinity 
[232,233]. As the interaction with the Pit-1 TAD was picked up at 
high salt concentration (favoring hydrophobic interactions), these 
hydrophobic patches sem likely interaction surfaces. The CR-3 
domain might require an intact zinc finger in order to optimally 
present this hydrophobic patch to the Pit-1 TAD. 
Transcription activation by Pit-1 involves recruitment of the 
coactivator CBP [46]. Furthermore, it has been shown that CBP can 
acetylate Pit-1 in vitro and that the presence of E1A can block this 
acetylation [79]. This implies that these three proteins can form a 
complex and modulate each other’s activity. Formation of such a 
ternary complex would provide an environment where the 
hydrophobic contacts, which are involved in Pit-1/CR-3 interaction, 
could actually take place in vivo. It is therefore tempting to speculate 
that, within the context of a ternary complex with CBP, E1A 13S 
causes an inhibition of the acetylation function of CBP by directly 
interacting with Pit-1. The 12S splice variant, which does not bind 
directly to Pit-1, would not be able to modulate the enzymatic activity 
of CBP in the same way. This model would assume that acetylation of 
Pit-1 positively regulates its transactivation capability, which is in 
keeping with the suggested effect of acetylation on Ets-1 binding in 
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chapter III. In order to verify this model, one could co-transfect wild 
type or acetylation deficient mutants of CBP, which would counter the 
repressive effect of E1A 13S on Pit-1 activation. Alternatively, 
binding of E1A 13S might physically block functional interactions of 
proteins other than CBP with the Pit-1 TAD. This would result in 
repression of Pit-1 ransactivation function by E1A 13S, but not by 
12S. 
Since Pit-1 is almost exclusively expressed in the pituitary 
gland, which is not a likely tissue for adenovirus infection , it seems 
unlikely that the Pit-1 / E1A interaction reported here occurs in the 
same manner in cell types that endogenously express Pit-1. Th re are, 
however, cellular proteins that can substitute for E1A functions. Such 
factors were supposed to be responsible for replication of E1A 
deficient adenovirus in embryonic carcinoma cells [238,239]. One 
specific example of such an E1A-like factor is the basic helix-loop-
helix factor Twist, which can interact with CBP/p300 in an analogous 
manner to E1A [240]. It is possible that such a factor is involved in the 
regulation of Pit-1 activity, for instance (given the differential effect of 
E1A 13S on the GH and PRL promoters) to restrict GH expression in 
non-somatotropes. Alternatively, the effects of E1A 13S on Pit-1 i U-
2 OS cells might reflect the fact that E1A needs to be able to interact 
with a host of cellular proteins and therefore needs to be rather 
promiscuous in its contacts. 
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 Summary / General Discussion 
 
Pit-1 is a pituitary specific transcription factor that plays a 
central role in the development and maintenance of a number of cell 
lineages in the anterior pituitary gland. In these cell lineages, Pit-1 is 
required for the selective expression of the growth hormone (GH), 
prolactin (PRL) and the b-subunit of the thyroid-st mulating hormone 
(TSHb). Pit-1 contains a POU DNA-binding domain, which consist of 
two independent DNA-binding modules (the POU-specific domain 
(POUs) and the POU-homeodomain (POUhd)), separated by a flexible 
linker. Loss of Pit-1 function leads to combined pituitary hormone 
deficiency (CPHD) syndrome, the main feature of which is dwarfism.
Chapter II of this thesis describes a clinical case study of a 
CPHD patient carrying two novel mutations (each on a different 
allele) in both e POUs and the POUhd. One of these mutations, 
located in the POUs, substitutes one of the hydrophobic core residues 
with a charged residue, which leads to a misfolded POUs domain that 
is unable to bind DNA. The other mutation leads to the deletion of the 
entire DNA-recognition helix from the POUhd. In the context of the 
full-length POU-domain, neither of these mutants was capable of 
high-affinity DNA-binding in vitro or stimulation of the Pit-1 target 
promoters in vivo. Therefore, the structural integrity of both the POUs 
and POUhd is required for high-affinity, sequence-specific DNA 
binding by Pit-1 and this DNA binding is essential for the function of 
Pit-1 in vivo.  
The expression of GH, PRL and TSHb is highly restricted to 
their respective cell lineage, while Pit-1 is present in all three cell 
lineages. Therefore, Pit-1 needs to cooperate with other transcription 
regulators in order to silence or activate its target promoters. The 
interaction of Pit-1 with two such factors, Ets-1 and GATA-2, is 
studied in chapter III. Ras-responsive Ets-1 cooperates with Pit-1 to 
synergistically activate the PRL promoter, which contains composite 
Ets-1 / Pit-1 recognition sites. However, both proteins can also 
associate in solution, in absence of DNA. This physical interaction 
involves the POUhd of Pit-1 and a part of the region III activation 
domain of Ets-1. Using nuclear magnetic resonance (NMR) monitored 
protein-protein titrations, we were able to study which residues on the 
POUhd are likely contacted by Ets-1. The NMR data gathered on the 
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minimal interaction domains suggests that Ets-1 binds the POUhd 
through multiple interacting regions, which is in agreement with 
previous biochemical work. 
One of the possible int racting regions on the POUhd mapped 
by the NMR analysis is the site of regulated phosphorylation. Indeed, 
introducing a phospho-mimicking group (an amino acid with a 
pronounced negatively charged side-chain, like an aspartic acid) at the 
phosphorylation site of the POUhd decreased the binding affinity for 
Ets-1 by about 30%. This is a remarkable result, as it is the first 
demonstrated effect of Pit-1 phosphorylation on a protein-protein 
interaction. For that reason it would be intriguing to study the effec  of 
this phospho-mimicking mutation on the stimulation of not only the 
PRL, but also the GH and TSHb promoters in transient transfections. 
The NMR and biochemical data indicate that, analogous to 
phosphorylation, regulated acetylation of one particular POUhd lysine 
residue may affect the binding affinity for Ets-1 by al ering the 
accessibility of another interacting region on the POUhd. This is an 
interesting observation; given the facts that Pit-1 can be acetylated by 
CBP in vitro and that both Ets-1 and Pit-1 are able to bind CBP. 
Whether acetylation of the POUhd is of any consequence for Ets-1 
binding remains to be determined. One approach would be in vitro 
acetylation of Pit-1, followed by interaction assays and coupled with 
mass spectrometry to verify whether the suggested residue is actually 
acetylated. Additionally, the in vivo acetylation state of Pit-1 needs to 
be determined. This may be done by creating a stably transfected 
pituitary cell line, expressing a HA-t gged Pit-1. Such a tagged 
version of Pit-1 may be immune-pr cipitated from a nuclear extract 
and analyzed by mass spectrometry. 
It is as yet unclear exactly how the physical interaction 
contributes to the functional synergism of Ets-1 and Pit-1. In fact, 
substitution of the interaction region on Ets-1 with the corresponding 
region from Ets-2 or the VP-16 activation domain abolished the 
physical interaction, but not the functional synergism in transient 
transfections (Dawn Duvall, to be published). This effect might be 
explained by targeting of both factors to the PRL-promoter through 
their respective DNA binding domains, which would imply that the 
physical interaction prior to promoter binding is of no functional 
relevance. However, our results imply that the physical association of 
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Pit-1 and Ets-1 is regulated by the post-translational state of Pit-1. If 
this is the case, than it is likely that at a cellular level the physical 
interaction presents an additional layer of control for the regulation of 
PRL expression. 
At present, it is unknown whether the physical association of 
Ets-1 and Pit-1 affects the DNA binding specificity or affinity of 
either protein. Such effects have been shown for the interactions of 
Pit-1 with GATA-2 (altered specificity of DNA binding by GATA-2) 
and Ets-1 with AML1/CBFa2 (increased affinity through alleviation 
of Ets-1 auto-inhibition of DNA binding). Since the interaction 
interface on the POUhd for both DNA and Ets-1 binding overlap to a 
large extent, it would not be surprising if the DNA binding affinity of 
the POUhd were somehow affected by Ets-1. However, the study 
described in chapter IV shows that, at least for the minimal interaction 
domain of Ets-1, this is not the case. This study did not address 
whether the auto-inhibition of DNA binding by Ets-1 is affected by
the interaction with Pit-1. Given the location of the interaction domain 
on p68 Ets-1 (residues 190-257), just N-terminally one of the two 
auto-inhibitory modules (residues 280-331), such an effect would not 
be farfetched. It will be interesting to directfutur  study towards 
EMSA analysis using the full-length Pit-1 and Ets-1 proteins and 
structure determination of the full-length proteins bound to the PRL-
4P composite element by crystallography. 
Chapter V investigates the functional relevance of a novel 
interaction of the conserved region 3 (CR-3) of the 13S splice variant 
of the adenovirus immediate early gene product (E1A 13S) with the 
N-terminal activation domain of Pit-1. Transient co-transfection of 
Pit-1 with E1A 13S showed an inhibitory effect of E1A 13S on Pit-1 
mediated stimulation of the GH and PRL promoters. This effect could 
be caused by simple masking of the activation domain of Pit-1, or 
alternatively might be caused by an inhibition of the acetylation 
function of CBP by E1A 13S. Such an inhibition of CBP mediated Pit-
1 acetylation by E1A has been shown in vitro. Therefore, it is 
tempting to speculate that acetylation by CBP might not only increase 
Pit-1 binding affinity for Ets-1 (chapter III), but might also enhance 
Pit-1 transcription activation efficiency in general. Future study should 
address whether any residues on Pit-1 are acetylated by CBP in vivo 
and if so, to what functional effect. In addition to the approach 
Summary / Discussion 
 113
mentioned above, this may be done by using acetylation mutants of 
CBP in co-transfections with Pit-1 and E1A 13S.
 Samenvatting / Algemene discussie 
Pit-1 is een transcriptiefactor die specifiek in de hypofyse tot 
expressie komt. Hier speelt Pit-1 een centrale rol in de ontwikkeling en 
overleving van een aantal hormoonproducerende cellijnen. In deze 
cellijnen is de aanwezigheid van Pit-1 oodzakelijk voor de selectieve 
expressie van groeihormoon (GH), prolactine (PRL) en de b-subunit van 
het thyroid-stimulerend hormoon (TSHb). Pit-1 bevat een POU DNA-
bindend domein, dat bestaat uit twee onafhankelijke DNA-bindende 
modules (het POU-specifieke domein (POUs) en het POU-homeodomein 
(POUhd)), die verbonden zijn door een flexibele linker. Verlies van de 
functie van Pit-1 leidt tot het CPHD syndroom, dat gekenmerkt wordt 
door deficientie van een aantal van de in de hypofyse geproduceerde 
hormonen. Het belangrijkste gevolg hiervan is dwerggroei. 
Hoofdstuk II van dit proefschrift beschrijft een klinische casus van 
een CPHD patiënt met twee nieuwe mutaties (elk op een apart allel) in 
zowel het POUs als het POUhd. Bij één van deze mutaties is een apolair 
residu dat deel uitmaakt van de hydrofobe binnenkant van het POUs, 
vervangen voor een geladen residu. Dit heeft een ontvouwing van het 
POUs tot gevolg, waardoor dit domein niet meer aan DNA kan binden. De 
andere mutatie leidt tot een deletie van de gehele DNA-herkennings helix 
van het POUhd. Geen van beide mutanten was, binnen de context van het 
gehele POU-domein, in staat om met enige affiniteit DNA te binden in 
vitro, of een Pit-1 afhankelijke promoter te activeren in vivo. Hieruit 
kunnen we concluderen, dat de structurele integriteit van zowel het POUs 
als het POUhd noodzakelijk is voor hoge affiniteit en sequentie-specifi ke 
DNA binding van Pit-1 en dat deze DNA binding essentiëel is voor het 
functioneren van Pit-1 in vivo. 
Hoewel Pit-1 in alle drie de cellijnen aanwezig is, blijft de 
expressie van zowel GH, PRL als TSHb beperkt tot zijn eigen hormoon 
producerende cellijn. Hieruit volgt, dat Pit-1 moet samenwerken met 
andere transcriptieregulerende factoren om de promoters van deze 
hormonen ofwel te activeren, ofwel te remmen. In hoofdstuk III wordt de 
interactie bestudeer  tussen Pit-1 en twee van zulke factoren, Ets-1 en 
GATA-2. Ets-1 is een transcriptiefactor die via de Ras signaaltransductie 
route geactiveerd kan worden. Samen met Pit-1 zorgt Ets-1 voor een 
synergistische activatie van de PRL promoter, waarin zich een 
samengestelde Ets-1 / Pit-1 herkenningssequentie bevindt. Beide eiwitten 
kunnen ook onafhankelijk van DNA aan elkaar binden. Bij deze fysieke 
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interactie bindt het POUhd van Pit-1 aan een deel van het activatiedomein 
van Ets-1. Met behulp van magnetische kernspin resonantie (NMR) werd 
een eiwit-eiwit titratie van het POUhd met het interactie domein van Ets-1 
gevolgd. Hierbij werd onderzocht welke residuen van het POUhd 
betrokken zijn bij de interactie met Ets-1. De NMR gegevens wijzen erop 
dat meer dan één gebied aan de oppervlakte van het POUhd betrokken is 
bij de binding van het minimale interactiedomein van Ets-1, wat 
overeenkomt met eerdere biochemische data. 
De plaats waar één van de mogelijke contactpunten tussen Ets-1 en 
het POUhd zich bevindt, kan in vivo gefosforyleerd worden. Een Pit-1 
mutant, waarbij fosforylering op die plaats wordt nabootst (door het 
introduceren van een aminozuur met een negatief geladen zijketen, 
bijvoorbeeld een aspartaat), verliest inderdaad 30% van zijn affiniteit voor 
Ets-1. Dit is een opzienbarend resultaat, omdat dit het eerste voorbeeld is 
van een eiwit-eiwit interactie van Pit-1, die waarschijnlijk gereguleerd 
wordt door fosforylering. Het zou daarom interessant zijn, om het effect 
van deze mutant op de stimulatie van niet allee  de PRL, maar ook de GH 
en TSHb promoters te testen in transiënte transfecties. De NMR en 
biochemische resultaten wijzen erop dat, analoog aan fosforylering, ook 
acetylering van een lysine residu in het POUhd de bindingsaffiniteit voor 
Ets-1 zou kunnen reguleren. Deze acetylering zou namelijk de 
toegankelijkheid van één van de interactiegebieden voor Ets-1 op het
POUhd kunnen verbeteren. Gezien het feit dat Pit-1 in vitro geacetyleerd 
kan worden door CBP en dat zowel Ets-1 als Pit-1 aan CBP kunnen 
binden, is zo’n regulatie via acetylering niet ondenkbaar. Of acetylering 
van het POUhd ook werkelijk invloed heeft op Ets-1 binding, moet nog 
worden vastgesteld. Om dit te testen zou in vitr acetylering van Pit-1, 
gevolgd door interactie assays met Ets-1, gecombineerd moeten worden 
met massa- pectrometrie om de acetylatie-status van gebonden Pit-1 te 
bepalen. Daarnaast zou de in vivoacetylatie-status van Pit-1 bepaald 
moeten worden. Een mogelijke benadering hiervoor is een stabiel 
getransfecteerde cellijn van hypofysecellen te creëren, die Pit-1 met 
bijvoorbeeld een HA-tag tot expressie brengt. Met behulp van deze 'tag' 
zou Pit-1 uit deze cellen geï soleerd kunnen worden, om vervolgens met 
behulp van massa- pectrometrie onderzocht te worden. 
Het is op dit moment nog niet duidelijk wat de precieze bijdrage is 
van de fysieke interactie tussen Ets-1 en Pit-1 aan het functionele 
synergisme van de twee factoren op de PRL promoter. Sterker nog, 
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wanneer het gebied van Ets-1, dat verantwoordelijk is voor de bindingvan 
Pit-1, wordt vervangen voor het overeenkomstige gebied uit Ets-2 of zelfs 
het activatie domein van VP-16, wordt er nog wel functioneel synergisme 
in transfecties waargenomen, terwijl er geen fysieke interactie meer is 
(Dawn Duvall, nog te publiceren materiaal). Deze resultaten zijn te 
verklaren, met het feit dat beide factoren nog steeds afzonderlijk de PRL 
promoter herkennen via hun DNA-bindend domein, wat impliceert dat de 
fysieke interactie geen functioneel belang heeft. Onze resultaten wijzen er 
echter op dat de associatie van Pit-1 en Ets-1 gereguleerd wordt door de 
post-translationele status van Pit-1. In dit licht is het waarschijnlijk dat de 
fysieke associatie een extra controleniveau creëert voor de regulatie van 
PRL expressie.  
Op dit moment is het nog niet bekend of de fysieke interactie 
tussen Ets-1 en Pit-1 de DNA-bindingsaffiniteit of -specificiteit van één 
van beide eiwitten beï nvloedt. Zulke effecten zijn bekend voor de 
interacties tussen Pit-1 en GATA-2 (veranderde specificiteit van GATA-
2) en tussen Ets-1 en AML1/CBFa2 (verhoogde affiniteit van Ets-1, door 
het opheffen van de auto-inhibitie van DNA-binding van Ets-1). Omdat de 
interactiegebieden voor Ets-1 en het DNA-bindende deel van het POUhd 
elkaar grotendeels overlappen, zou het niet verassend zijn als de DNA-
bindingsaffiniteit van het POUhd gemoduleerd zou worden door Ets-1. De 
studie die beschreven staat in hoofdstuk IV toont echter aan dat dit, voor 
het minimale interactiedomein van Ets-1, ie  het geval is. In deze studie 
wordt niet gekeken naar enig effect van Pit-1 op de auto-inhibitie van 
DNA-binding van Ets-1. Gezien de lokatie van het Pit-1 interactiedomein 
op p68-Ets-1 (van residu 190-257), net N-terminaal van een van de twee 
auto-inhibitie modules (residu 280-331), zou zo’n effect niet vergezocht 
zijn. Darom zal het interessant zijn, om bij toekomstige studies (zoals 
bijvoorbeeld mobiliteits proeven (EMSA) en structuuropheldering m.b.v. 
kristallografie) de volledige eiwitten te gebruiken. 
In hoofdstuk V wordt de functionele relevantie van een nieuw 
gevonden interactie tussen het activatiedomein van Pit-1 en de conserved 
region 3 (CR-3) van de 13S splice variant van het adenovirus immediate 
early gen product (E1A 13S) onderzocht. Transiënte co-transf cties van 
Pit-1 met E1A 13S lieten een remmend effect zien van E1A 13S op de 
door Pit-1 geactiveerde GH en PRL promoters. Dit effect zou veroorzaakt 
kunnen worden door maskering van het activatiedomein van Pit-1 door de 
binding van E1A 13S. Anderzijds, zou de inhibitie van de 
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acetyleringsfunctie van CBP door E1A 13S kunnen leiden tot remming 
van de geteste promoters. E1A is in staat de acetylering van Pit-1 door 
CBP te remmen in vitro. Het is daarom verleidelijk om te speculeren dat 
acetylering van Pit-1 door CBP niet alleen de bindingsaffiniteit voor Ets-1 
zou kunnen doen toenemen (hoofdstuk III), maar ook de algemene 
efficiëntie van transcriptieactivatie van Pit-1. Toekomstige studie zal 
moeten uitwijzen of er in vivo residuen van Pit-1 geacetyleerd worden 
door CBP en wat de eventuele functionele consequenties daarva  zijn. 
Naast de al eerder genoemde benadering, zouden hiervoor mutanten van 
CBP, die gestoord zijn in hun acetyleringsfunctie, gebruikt kunnen 
worden in co-transfecties met Pit-1 en E1A 13S.
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